<SEC-DOCUMENT>0001104659-25-113886.txt : 20251119
<SEC-HEADER>0001104659-25-113886.hdr.sgml : 20251119
<ACCEPTANCE-DATETIME>20251119062342
ACCESSION NUMBER:		0001104659-25-113886
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251118
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251119
DATE AS OF CHANGE:		20251119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AVADEL PHARMACEUTICALS PLC
		CENTRAL INDEX KEY:			0001012477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37977
		FILM NUMBER:		251496589

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		10 EARLSFORT TERRACE
		CITY:			DUBLIN 2
		PROVINCE COUNTRY:   	L2
		ZIP:			D02 T380
		BUSINESS PHONE:		636-449-1830

	MAIL ADDRESS:	
		STREET 1:		16640 CHESTERFIELD GROVE ROAD
		STREET 2:		SUITE 200
		CITY:			CHESTERFIELD
		STATE:			MO
		ZIP:			63005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLAMEL TECHNOLOGIES SA
		DATE OF NAME CHANGE:	19960422
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2529228d13_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:avdl="http://avadel.com/20251118">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_avdl_avadel.com_20251118 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20251118_20251118 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001012477 -->
<!-- Field: Set; Name: xdx; ID: xdx_071_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\EntityInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000004" name="dei:EntityCentralIndexKey">0001012477</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avdl-20251118.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-11-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-18</xbrli:startDate>
        <xbrli:endDate>2025-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_907_edei--DocumentType_c20251118__20251118_zRtrOF3lFhw7"><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="font-size: 10pt">Pursuant
to Section 13 or Section 15(d)</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="font-size: 10pt">of the Securities Exchange Act of 1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Date of Report
(Date of earliest event reported)</b>: <span id="xdx_90B_edei--DocumentPeriodEndDate_c20251118__20251118_z7SPNE43dVC2"><ix:nonNumeric contextRef="AsOf2025-11-18" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">November 18, 2025</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityRegistrantName_c20251118__20251118_zaOWsmGes5Mk"><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000012" name="dei:EntityRegistrantName">AVADEL PHARMACEUTICALS PLC</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Exact name of registrant as specified
in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20251118__20251118_zLTLZDxgXXw7"><ix:nonNumeric contextRef="AsOf2025-11-18" format="ixt-sec:edgarprovcountryen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Ireland</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20251118__20251118_zVVEFWGe0RLh"><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000014" name="dei:EntityFileNumber">001-37977</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20251118__20251118_zOXdO1E3LE64"><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000015" name="dei:EntityTaxIdentificationNumber">98-1341933</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(Commission</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(IRS Employer</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">of incorporation)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">File Number)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_907_edei--EntityAddressAddressLine1_c20251118__20251118_zwBGClMHtKHd"><b><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000016" name="dei:EntityAddressAddressLine1">10
        Earlsfort Terrace</ix:nonNumeric></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityAddressCityOrTown_c20251118__20251118_zM37SOUa1pf3"><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000017" name="dei:EntityAddressCityOrTown">Dublin 2</ix:nonNumeric></span></b>, <b><span id="xdx_90D_edei--EntityAddressCountry_c20251118__20251118_zN86lKHotvrk"><ix:nonNumeric contextRef="AsOf2025-11-18" format="ixt-sec:countrynameen" id="Fact000018" name="dei:EntityAddressCountry">Ireland</ix:nonNumeric></span>,</b><b> <span id="xdx_909_edei--EntityAddressPostalZipCode_c20251118__20251118_zlzcak9zulQ6"><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000019" name="dei:EntityAddressPostalZipCode">D02
T380</ix:nonNumeric></span></b></p></td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; width: 50%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Not Applicable</b></p></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code</b><span style="font-style: normal">:</span> <b>+<span id="xdx_908_edei--CityAreaCode_c20251118__20251118_zH7NUvlZq2o9"><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000020" name="dei:CityAreaCode">353</ix:nonNumeric> </span></b><b><span id="xdx_90C_edei--LocalPhoneNumber_c20251118__20251118_zCYShJRmkWl7"><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000021" name="dei:LocalPhoneNumber">1 901 5201</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address,
if changed since last report)</p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation       to the registrant under any of the following provisions:</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90A_edei--WrittenCommunications_c20251118__20251118_zCADRbR6hEp8"><ix:nonNumeric contextRef="AsOf2025-11-18" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90E_edei--SolicitingMaterial_c20251118__20251118_ziXUAjyO4wkc"><ix:nonNumeric contextRef="AsOf2025-11-18" format="ixt:booleantrue" id="Fact000023" name="dei:SolicitingMaterial">x</ix:nonNumeric></span></span></span></span></td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementTenderOffer_c20251118__20251118_zvTREofUZwG2"><ix:nonNumeric contextRef="AsOf2025-11-18" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20251118__20251118_zbNtpdEBrLPh"><ix:nonNumeric contextRef="AsOf2025-11-18" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered pursuant to Section
12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 1pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="text-align: left; vertical-align: bottom">
    <td style="border: Black 1pt solid; width: 40%; font-size: 10pt; text-align: center"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 20%; font-size: 10pt; text-align: center"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 40%; font-size: 10pt; text-align: center"><span style="font-size: 10pt">Name of each exchange on which <br/>
registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_905_edei--Security12bTitle_c20251118__20251118_zdSnGEgQEiIk"><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000026" name="dei:Security12bTitle">Ordinary
Shares, nominal value $0.01 per share</ix:nonNumeric></span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_904_edei--TradingSymbol_c20251118__20251118_z0m79iVoqxg"><ix:nonNumeric contextRef="AsOf2025-11-18" id="Fact000027" name="dei:TradingSymbol">AVDL</ix:nonNumeric></span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_edei--SecurityExchangeName_c20251118__20251118_z9j9z4iZhbw9"><ix:nonNumeric contextRef="AsOf2025-11-18" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Global Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20251118__20251118_zDxhuV55vLTk"><ix:nonNumeric contextRef="AsOf2025-11-18" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; font-size: 10pt"><span style="font-size: 10pt"><b>Item 1.01</b></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b>Entry into a Material Definitive Agreement. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">On November 18, 2025 (the &#8220;Amendment Date&#8221;),
Avadel Pharmaceuticals plc, a public limited company incorporated under the laws of Ireland (&#8220;Avadel&#8221;), entered into Amendment
No. 1 (the &#8220;Amendment&#8221;) to the previously announced Transaction Agreement, dated October 22, 2025 (the &#8220;Original Transaction
Agreement&#8221; and, as amended by the Amendment, the &#8220;Amended Transaction Agreement&#8221;), by and between Avadel and Alkermes
plc (&#8220;Alkermes&#8221;). Capitalized terms used herein but not otherwise defined herein shall have the meanings assigned to them
in the Original Transaction Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">As previously announced, the Original Transaction
Agreement provided that Alkermes would acquire the entire issued and to be issued ordinary share capital of Avadel for (i) $18.50 per
ordinary share, nominal value $0.01 per share, of Avadel (each, an &#8220;Avadel Share&#8221;), payable in cash at closing (the &#8220;Cash
Consideration&#8221;) and (ii) a non-transferable contingent value right (the &#8220;CVR&#8221;) entitling holders to a potential additional
cash payment of $1.50 per Avadel Share, contingent upon achievement of the specified milestone set forth in the CVR Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Amendment, the parties have
agreed, among other things, on the terms of an increased offer to acquire the entire issued and to be issued ordinary share capital of
Avadel with the Cash Consideration payable under the Amended Transaction Agreement increased to $21.00 per Avadel Share and with the terms
of the CVR unchanged.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Other than as expressly modified pursuant to the
Amendment, the Original Transaction Agreement remains in full force and effect as originally executed on October 22, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">The foregoing descriptions of the Original Transaction
Agreement and the Amendment do not purport to be complete and are subject to, and qualified in their entirety by reference to, the full
text of the Original Transaction Agreement, a copy of which is incorporated by reference as Exhibit 2.1 to this Current Report on Form
8-K and is incorporated herein by reference, and the full text of the Amendment, a copy of which is filed as Exhibit 2.2 to this Current
Report on Form 8-K and is incorporated into this Item 1.01 by reference, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">The Amendment has been filed as an exhibit herewith
pursuant to the applicable rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) to provide investors
with information regarding its terms. It is not intended to provide any other factual information about Avadel, Alkermes or their respective
subsidiaries or affiliates or to modify or supplement any factual disclosures about Avadel or Alkermes included in their respective public
reports filed with the SEC. The Amendment should not be read alone, but should instead be read in conjunction with the Original Transaction
Agreement which it amends and the other information regarding the Amended Transaction Agreement, the transactions contemplated by the
Amended Transaction Agreement, Avadel, Alkermes, their respective affiliates and their respective businesses that will be contained in,
incorporated by reference into, or attached as an exhibit or annex to the definitive proxy statement that Avadel will file with the SEC
in connection with the transactions contemplated by the Amended Transaction Agreement, as may be further amended or supplemented from
time to time, as well as in the other filings that each of Avadel or Alkermes files or furnishes with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">References to the Original Transaction Agreement
from and after the entry into the Amendment on November 18, 2025 refer to the Amended Transaction Agreement as amended by the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; font-size: 10pt"><span style="font-size: 10pt"><b>Item 7.01.</b></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b>Regulation FD Disclosure.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">On November 19, 2025, Avadel and Alkermes issued
a revised offer announcement announcing entry into the Amendment. A copy of the revised offer announcement is furnished herewith as Exhibit
99.1 and incorporated by reference into this Item 7.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">The information in this Item 7.01, and in Exhibit
99.1 furnished herewith, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; font-size: 10pt"><span style="font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><a href="https://www.sec.gov/Archives/edgar/data/1012477/000110465925101430/tm2529228d2_ex2-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">2.1</span></a></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: justify; width: 88%"><a href="https://www.sec.gov/Archives/edgar/data/1012477/000110465925101430/tm2529228d2_ex2-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Transaction Agreement, dated as of October 22, 2025, by and between Alkermes plc and Avadel Pharmaceuticals plc. (incorporated by reference to Exhibit 2.1 to Avadel&#8217;s Current Report on Form 8-K filed with the SEC on October 22, 2025).</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><a href="tm2529228d13_ex2-2.htm"><span style="font-size: 10pt">2.2 </span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="tm2529228d13_ex2-2.htm"><span style="font-size: 10pt">Amendment No. 1 to the Transaction Agreement, dated as of November 18, 2025, by and between Alkermes plc and Avadel Pharmaceuticals plc. </span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><a href="tm2529228d13_ex99-1.htm"><span style="font-size: 10pt">99.1</span></a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="tm2529228d13_ex99-1.htm"><span style="font-size: 10pt">Revised offer announcement, dated as of November 19, 2025.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover page interactive data file (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NO OFFER OR SOLICITATION</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report is for information purposes only and
is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase,
otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction,
pursuant to the acquisition by Alkermes of all outstanding ordinary shares of Avadel (the &#8220;acquisition&#8221;) or otherwise, nor
shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The acquisition will be implemented by means of
an Irish High Court-sanctioned scheme of arrangement on the terms provided for in the scheme document (or, if the acquisition is implemented
by way of a takeover offer, the applicable takeover offer document), which will contain the full terms and conditions of the acquisition,
including details of how Avadel shareholders may vote in respect of the acquisition. Any decision in respect of, or other response to,
the acquisition, should be made only on the basis of the information contained in the scheme document (or if the acquisition is implemented
by way of a takeover offer, the applicable takeover offer document).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b><i>Important
Additional Information and Where To Find It</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the acquisition, Avadel filed
a preliminary proxy statement (which includes a draft of the scheme document) with the SEC on November 13, 2025 and intends to file a
definitive proxy statement (which will include the scheme document). The definitive proxy statement will be sent to Avadel&#8217;s shareholders
as of the record date to be established for voting at Avadel shareholder meetings to approve the acquisition. This report is not a substitute
for the proxy statement or any other document that Avadel may file with the SEC or send to its shareholders in connection with the acquisition.
BEFORE MAKING ANY VOTING DECISION, AVADEL&#8217;S SHAREHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING THE SCHEME
DOCUMENT), ANY AMENDMENTS OR SUPPLEMENTS THERETO AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE
ACQUISITION, INCLUDING ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE ACQUISITION, THE PARTIES TO THE SCHEME AND RELATED MATTERS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any vote in respect of the resolutions to be proposed
at the Avadel shareholder meeting to approve the acquisition, the scheme or related matters, or other responses in relation to the acquisition,
should be made only on the basis of the information contained in the definitive proxy statement (including the scheme document).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preliminary and definitive proxy statements,
if and when filed, as well as Avadel&#8217;s other public filings with the SEC, may be obtained without charge at the SEC&#8217;s website
at www.sec.gov and at Avadel&#8217;s website at https://investors.avadel.com/sec-filings. Avadel shareholders and investors will also
be able to obtain, without charge, a copy of the preliminary and definitive proxy statements (including the scheme document) and other
relevant documents (when available) by directing a written request to Avadel Pharmaceuticals plc, Attn: Investor Relations, 16640 Chesterfield
Grove Road #200, Chesterfield, MO 63005, United States, or by contacting Investor Relations via email at investors@avadel.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PARTICIPANTS IN THE SOLICITATION</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avadel and certain of its directors, executive
officers and employees may be deemed to be participants in the solicitation of proxies from Avadel shareholders in connection with the
acquisition and any other matters to be voted on at Avadel shareholder meetings to approve the acquisition. Information about the directors
and executive officers of Avadel, including a description of their direct or indirect interests, by security holdings or otherwise, is
set forth in Avadel&#8217;s preliminary proxy statement on Schedule 14A for the proposed acquisition, dated and filed with the SEC on
November 13, 2025. Other information regarding the persons who may, under the rules of the SEC, be deemed to be participants in the solicitation
of Avadel shareholders, including a description of their direct or indirect interests, by security holdings or otherwise, are set forth
in the preliminary proxy statement (which includes a draft of the scheme document) and will be set forth in the definitive proxy statement
(which will contain the scheme document) and other relevant materials to be filed with the SEC in connection with the acquisition. You
may obtain free copies of these documents using the sources indicated above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by words
such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;seek,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;likely,&#8221; &#8220;depend,&#8221;
&#8220;should,&#8221; &#8220;would,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; and similar expressions, and
may include references to assumptions and relate to Avadel&#8217;s future prospects, developments and business strategies, and the acquisition.
Such forward-looking statements include, but are not limited to, statements relating to the acquisition involving Alkermes and Avadel,
Avadel&#8217;s current expectations and estimates about the expected effects and anticipated benefits of the acquisition, the date of
closing of the acquisition, including the parties&#8217; ability to satisfy the conditions to the consummation of the acquisition and
the other conditions set forth in the Amended Transaction Agreement, and Avadel&#8217;s business activities and strategies. Avadel&#8217;s
expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated
by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks
and uncertainties related to: (i) the ability of the parties to consummate the acquisition in a timely manner or at all; (ii) the satisfaction
(or waiver) of conditions to the consummation of the acquisition, including with respect to the approval of Avadel shareholders and required
regulatory approvals; (iii) the possibility that competing offers for Avadel may be made; (iv) potential delays in consummating the acquisition;
(v) the ability of Avadel to timely and successfully achieve the anticipated benefits of the acquisition; (vi) the impact of health pandemics
on the parties&#8217; respective businesses and the actions the parties may take in response thereto; (vii) the occurrence of any event,
change or other circumstance or condition that could give rise to the termination of the Amended Transaction Agreement; (viii) the effect
of the announcement or pendency of the acquisition on Avadel&#8217;s business relationships, operating results and business generally;
(ix) costs related to the acquisition; and (x) the outcome of any legal proceedings that may be instituted against the parties or any
of their respective directors or officers related to the Amended Transaction Agreement or the acquisition. Additional risks and uncertainties
that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included
under the caption &#8220;Risk Factors&#8221; and elsewhere in Avadel&#8217;s most recent filings with the SEC, including its Annual Report
on Form 10-K for the year ended December 31, 2024 and any subsequent reports on Form 10-Q or Form 8-K filed with the SEC from time to
time and available at www.sec.gov. These documents can be accessed on Avadel&#8217;s website at https://investors.avadel.com/sec-filings.
The forward-looking statements set out in this report are made only as of the date hereof. Avadel assumes no obligation and does not intend
to update these forward- looking statements, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>RESPONSIBILITY STATEMENT REQUIRED BY THE
IRISH TAKEOVER RULES</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors of Avadel accept responsibility
for the information contained in this report. To the best of the knowledge and belief of the directors of Avadel (who have taken all reasonable
care to ensure such is the case), the information contained in this report is in accordance with the facts and does not omit anything
likely to affect the import of such information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>IMPORTANT NOTICES RELATING TO FINANCIAL
ADVISORS</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goldman Sachs &amp; Co. LLC, which is authorized
and regulated by the Financial Industry Regulatory Authority, is acting exclusively as financial advisor for Avadel and for no one else
in connection with the matters set out in this report and will not regard any other person as its client in relation to the matters set
out in this report and will not be responsible to anyone other than Avadel for providing the protections afforded to clients of Goldman
Sachs &amp; Co. LLC nor for providing advice in relation to the acquisition or any other matter referred to in this report. Neither Goldman
Sachs &amp; Co. LLC nor any of its affiliates (nor their respective directors, officers, employees or agents) owes or accepts any duty,
liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person
who is not a client of Goldman Sachs &amp; Co. LLC in connection with this report, any statement contained herein or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Morgan Stanley &amp; Co. LLC, acting through its
affiliate Morgan Stanley &amp; Co. International plc (together, &#8220;Morgan Stanley&#8221;), which is authorised by the Prudential Regulation
Authority and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for Avadel as financial advisor
and for no one else in relation to the matters referred to in this report. In connection with such matters, Morgan Stanley and its directors,
officers, employees and agents will not regard any other person as its client, nor will it be responsible to anyone other than Avadel
for providing the protections afforded to their clients or for providing advice in connection with the matters described in this announcement
or any matter referred to herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>DEALING DISCLOSURE REQUIREMENTS OF THE IRISH
TAKEOVER RULES</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the provisions of Rule 8.3(a) of the Irish
Takeover Panel Act 1997, Takeover Rules, 2022 (&#8220;Irish Takeover Rules&#8221;), any person who is &#8216;interested&#8217; (directly
or indirectly) in 1% or more of any class of &#8216;relevant securities&#8217; of Avadel must make an &#8216;opening position disclosure&#8217;
following the commencement of the &#8216;offer period&#8217;. An &#8216;opening position disclosure&#8217; must contain the details contained
in Rule 8.6(a) of the Irish Takeover Rules, including, among other things, details of the person&#8217;s &#8216;interests&#8217; and &#8216;short
positions&#8217; in any &#8216;relevant securities&#8217; of Avadel. An &#8216;opening position disclosure&#8217; by a person to whom
Rule 8.3(a) applies must be made by no later than 3:30 p.m. (U.S. Eastern Time) on the day falling ten &#8216;business days&#8217; following
the commencement of the &#8216;offer period&#8217;. Relevant persons who deal in any &#8216;relevant securities&#8217; prior to the deadline
for making an &#8216;opening position disclosure&#8217; must instead make a &#8216;dealing&#8217; disclosure as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the provisions of Rule 8.3(b) of the Irish
Takeover Rules, if any person is, or becomes, &#8216;interested&#8217; (directly or indirectly) in 1% or more of any class of &#8216;relevant
securities&#8217; of Avadel, that person must publicly disclose all &#8216;dealings&#8217; in any &#8216;relevant securities&#8217; of
Avadel during the &#8216;offer period&#8217;, by no later than 3:30 p.m. (U.S. Eastern Time) on the &#8216;business day&#8217; following
the date of the relevant transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If two or more persons cooperate on the basis
of any agreement either express or tacit, either oral or written, to acquire an &#8216;interest&#8217; in &#8216;relevant securities&#8217;
of Avadel or any securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover
Rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, each of Avadel and any offeror must
make an &#8216;opening position disclosure&#8217; by no later than 12:00 noon (U.S. Eastern Time) on the date falling ten &#8216;business
days&#8217; following the commencement of the &#8216;offer period&#8217; or the announcement that first identifies a securities exchange
offeror, as applicable, and disclose details of any &#8216;dealings&#8217; by it or any person &#8216;acting in concert&#8217; with it
in &#8216;relevant securities&#8217; during the &#8216;offer period&#8217;, by no later than 12:00 noon (U.S. Eastern Time) on the business
day following the date of the transaction (see Rules 8.1, 8.2 and 8.4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A disclosure table, giving details of the companies
in whose &#8216;relevant securities&#8217; &#8216;opening position&#8217; and &#8216;dealings&#8217; should be disclosed can be found
on the Irish Takeover Panel&#8217;s website at www.irishtakeoverpanel.ie.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Interests&#8221; in securities arise, in
summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular,
a person will be treated as having an &#8216;interest&#8217; by virtue of the ownership or control of securities, or by virtue of any
option in respect of, or derivative referenced to, securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Terms in quotation marks in this section are defined
in the Irish Takeover Rules, which can be found on the Irish Takeover Panel&#8217;s website. If you are in any doubt as to whether or
not you are required to disclose an &#8216;opening position&#8217; or &#8216;dealing&#8217; under Rule 8, please consult the Irish Takeover
Panel&#8217;s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>ADDITIONAL INFORMATION</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain capitalized words used in this report
and not herein defined have the meanings given to such words in the Rule 2.7 Announcement dated October 22, 2025, as revised on November
19, 2025, issued by Avadel and Alkermes (the &#8220;Rule 2.7 Announcement&#8221;). The bases and sources set out in the Rule 2.7 Announcement
have been used in this report, unless otherwise stated or the context otherwise requires.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The release, publication or distribution of this
report in, into, or from, certain jurisdictions other than Ireland and the United States may be restricted or affected by the laws of
those jurisdictions. Accordingly, copies of this report are not being, and must not be, mailed or otherwise forwarded, distributed or
sent in, into, or from any such jurisdiction. Therefore, persons who receive this report (including without limitation nominees, trustees
and custodians) and are subject to the laws of any jurisdiction other than Ireland and the United States who are not resident in Ireland
and the United States will need to inform themselves about, and observe, any applicable restrictions or requirements. Any failure to do
so may constitute a violation of the securities laws of any such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NO PROFIT FORECAST / QUANTIFIED FINANCIAL
BENEFIT STATEMENT / ASSET VALUATION</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No statement in this report is intended to constitute
a profit forecast or a quantified financial benefit statement for any period, nor should any statements be interpreted to mean that earnings
or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods. No statement in this
report constitutes an asset valuation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: November 19, 2025</span></td>
    <td colspan="3"><span style="font-size: 10pt"><b>AVADEL PHARMACEUTICALS PLC</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Jerad G. Seurer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">Name:</span></td>
    <td style="width: 42%"><span style="font-size: 10pt">Jerad G. Seurer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">General Counsel &amp; Corporate Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2WUrFfPAxMYksRCJ6XXKMJd2R2c3qk/rLNiUaBobh3nOvEL4oaKM6ZDiv6xKO2A+dtAg1tsioL+gc2XaXgrs1XpWxLLWd3h+YkWPQMatFFEsnTNZRGWxSCINlmCyjGIIwjROo9sL76hnpVjWorZIdSN1AxTSwQiv5NScc5ZM09a+p6oRsFGkXtwhm+Q1REEZwoFE+iG8GyjITnj+NJwqm++Bc+dOi/pKQd9i7OjPT//U+BuZKjQ== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>2
<FILENAME>tm2529228d13_ex2-2.htm
<DESCRIPTION>EXHIBIT 2.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AMENDMENT
NO. 1 TO the TRANSACTIOn AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Amendment No.&nbsp;1,
dated as of November&nbsp;18, 2025 (this &ldquo;<B>Amendment</B>&rdquo;), to the TRANSACTION AGREEMENT (the &ldquo;<B>Agreement</B>&rdquo;),
dated as of October&nbsp;22, 2025, is entered into by and between Alkermes plc, an Irish public limited company with registered number
498284 having its registered office at Connaught House, 1 Burlington Road, Dublin 4,&nbsp;Ireland D04 C5Y6 (&ldquo;<B>Parent</B>&rdquo;),
and Avadel Pharmaceuticals plc, an Irish public limited company with registered number 572535 having its registered office at 10 Earslfort
Terrace, Dublin 2,&nbsp;Ireland (the &ldquo;<B>Company</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, Parent and the Company,
have previously entered into the Agreement, relating to a recommended offer to be made by Parent for the entire issued and to be issued
ordinary shares, nominal value $0.01 per share, of the Company to be implemented by the Scheme or, at the election of Parent and subject
to the terms of the Transaction Agreement, by means of a takeover offer; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and Parent
desire to amend the Agreement in accordance with <U>Section&nbsp;10.5</U> of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and the covenants and agreements set forth in this Amendment, and other good and valuable consideration, the adequacy
and receipt of which hereby are acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT>All
capitalized terms used herein shall have the meanings set forth in the Agreement, unless the context indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><U>Section&nbsp;1.1</U>
of the Agreement is hereby amended by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>deleting
the definition of &ldquo;Cash Consideration&rdquo; and replacing it with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B>Cash Consideration</B>&rdquo; means $21.00 in cash
per Company Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>deleting
the definition of &ldquo;Financing Information&rdquo; in its entirety; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>deleting
the definition of &ldquo;End Date&rdquo; and replacing it with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">&ldquo;</FONT><B>End Date</B>&rdquo;
means the date that is twelve (12) months from the date of this Agreement, provided, that if the Completion shall not have occurred as
of the End Date and all the conditions to Completion, other than Conditions 1, 2.3, 2.4 and 3.1 (including as a result of a Government
Shutdown), would be satisfied if the Completion were to occur on such date, the End Date shall be automatically extended to the date that
is fifteen months (15) from the date of this Agreement, and such date shall be the End Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>deleting
the definition of &ldquo;Cap&rdquo; and replacing it with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B>Cap</B>&rdquo; means an amount equal to one percent
(1%) of the aggregate value of the total Cash Consideration payable with respect to the Company Shares in connection with the Acquisition
(excluding, for clarity, any interest in such share capital of the Company held by Parent or any Concert Parties of Parent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>deleting
the definition of &ldquo;Debt Agreement&rdquo; and replacing it with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">&ldquo;</FONT><B>Debt Agreement</B>&rdquo;
means that certain Amended and Restated Bridge Term Loan Credit Agreement, dated as of the First Amendment Effective Date, among Parent,
as a borrower, Alkermes,&nbsp;Inc., as a borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto,
an executed copy of which has been provided to the Company on the First Amendment Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>adding
the following definition of &ldquo;First Amendment Effective Date&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B>First Amendment Effective Date</B>&rdquo; means the
date on which Amendment No.&nbsp;1 to the Transaction Agreement was executed by Parent and the Company, which was, for avoidance of doubt,
November&nbsp;18, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT>The
last sentence of Section&nbsp;7.2(b)&nbsp;of the Agreement is hereby deleted and replaced in its entirety with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company will provide all information reasonably required
to enable Parent to make such Filings and to achieve the fulfilment of the conditions precedent and cooperate with Parent in its efforts
to comply with its obligations under this Agreement, including in seeking to obtain any required Clearances, including contesting any
Action commenced by any Governmental Entity in connection with the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><U>Section&nbsp;7.2(c)</U>&nbsp;of
the Agreement is hereby deleted and replaced in its entirety with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Notwithstanding <U>Section&nbsp;7.2(b)</U>&nbsp;or anything
else in this Agreement to the contrary, but subject in any event to <U>Section&nbsp;7.2(d)</U>, Parent shall promptly take the steps necessary
to obtain all Clearances under the HSR Act and each other Antitrust Law or foreign investment Law, including all jurisdictions listed
on <U>Section&nbsp;7.2(b)</U>&nbsp;of the Company Disclosure Schedule, so as to enable the parties to consummate the Acquisition and the
other transactions contemplated hereby as promptly as reasonably practicable and in any event on or before the End Date, including taking
the following actions to the extent required to obtain such Clearances: (i)&nbsp;committing to or effecting, by consent decree, hold separate
orders, trust, or otherwise, the sale, divestiture, license, transfer, assignment or other disposition of assets or businesses of the
Parent, its Subsidiaries or Affiliates or the Company, or any portions thereof, (ii)&nbsp;terminating, relinquishing, modifying, transferring,
assigning, restructuring or waiving existing agreements, collaborations, relationships, ventures, contractual rights, obligations or other
arrangements of the Parent, its Subsidiaries or Affiliates or the Company, (iii)&nbsp;creating or consenting to create any relationships,
ventures, contractual rights, obligations, behavioral undertakings or other arrangements of the Parent, its Subsidiaries or Affiliates
or the Company (or, in each case, agreeing or offering to agree to do the same) (any action contemplated by the preceding clauses (i)&nbsp;through
(iii), a &ldquo;<B>Remedy Action</B>&rdquo;) and (iv)&nbsp;contesting any Action brought by any Governmental Entity or other Person challenging
or seeking to enjoin, prevent or delay the closing of the Acquisition and the other transactions contemplated by this Agreement, <U>provided</U>,
<U>however</U>, that (A)&nbsp;any Remedy Action shall be conditioned upon the occurrence of the Completion unless Parent, in its sole
discretion, elects otherwise, and (B)&nbsp;the Company shall not, and shall cause its Subsidiaries not to, propose, offer, or commit to,
or otherwise take, any Remedy Action without the prior written consent of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><U>Section&nbsp;7.2(d)</U>&nbsp;of
the Agreement is hereby deleted and replaced in its entirety with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Parent shall have the right to (i)&nbsp;direct, devise and
implement the strategy for obtaining any necessary Clearance from and submitting filings to, for responding to any request from, inquiry
or investigation by (including directing the timing, nature and substance of all such responses), and lead all meetings and communications
(including any negotiations) with, any Governmental Entity that has authority to enforce any Antitrust Law, and (ii)&nbsp;control the
commencement, defense and settlement of any Action brought by or before any Governmental Entity that has authority to enforce any Antitrust
Law or foreign investment Law or any other Person pursuant to any Antitrust Law or foreign investment Law; provided, however, that Parent
shall reasonably consult with the Company and consider in good faith the views and comments of the Company in connection with the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT>The
second sentence of Section&nbsp;7.2(f)&nbsp;of the Agreement is hereby deleted and replaced in its entirety with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Subject to <U>Section&nbsp;7.2(d)</U>, none of the Company,
Parent or their respective Representatives shall agree to participate in any material or substantive meeting or conference (including
by telephone) with any Governmental Entity, or any member of the staff of any Governmental Entity, in respect of any Filing, Action (including
the settlement of any investigation) or other inquiry regarding the Acquisition or the Scheme unless it consults with the other party
in advance and, to the extent permitted by such Governmental Entity, allows the other party to participate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><U>Section&nbsp;7.2(h)</U>&nbsp;of
the Agreement is hereby deleted and replaced in its entirety with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">From the date of this Agreement through the earlier of the
termination of this Agreement or Completion, Parent shall not, and shall cause its Subsidiaries and Affiliates not to, acquire or agree
to acquire, by merging or consolidating with, or by purchasing a substantial portion of the assets of or equity interests in, or by any
other manner, any Person or portion thereof, or otherwise acquire or agree to acquire any assets, if the entering into of a definitive
agreement relating to, or the closing of such acquisition, merger or consolidation would reasonably be expected to (i)&nbsp;impose a material
delay in the obtaining of, or significantly increase the risk of not obtaining, any authorizations, consents, orders, declarations or
approvals of any Governmental Entity necessary to close the Acquisition and the other transactions contemplated by this Agreement or the
expiration or termination of any applicable waiting period, (ii)&nbsp;materially increase the risk of any Governmental Entity entering
an order prohibiting the closing of the Acquisition and the other transactions contemplated by this Agreement or (iii)&nbsp;materially
delay the closing of the Acquisition and the other transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><U>Section&nbsp;7.1(f)</U>&nbsp;of
the Agreement is hereby deleted in its entirety and such clause is reserved. All references in the Agreement to <U>Section&nbsp;7.1(f)</U>&nbsp;of
the Agreement and any cross-references, definitions, schedules, exhibits, or other provisions, only to the extent that any of the foregoing
refer to or rely upon <U>Section&nbsp;7.1(f)</U>, are hereby deleted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><U>Section&nbsp;7.7</U>
of the Agreement is hereby deleted in its entirety and such clause is reserved. All references in the Agreement to <U>Section&nbsp;7.7</U>
of the Agreement and any cross-references, definitions, schedules, exhibits, or other provisions, only to the extent that any of the foregoing
refer to or rely upon <U>Section&nbsp;7.7</U>, are hereby deleted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT>The
Company agrees that, following the execution of this Amendment, there is no Company Alternative Proposal made prior to the execution of
this Amendment that constitutes a Company Superior Proposal. If any Company Alternative Proposal is made following the execution of this
Amendment (including any amendment to any Company Alternative Proposal made prior to such execution), the Company shall treat each such
Company Alternative Proposal as a new Company Alternative Proposal for purposes of <U>Section&nbsp;5.2</U> of the Agreement (including,
for the avoidance of doubt, that the notice period for any notification delivered following the execution of this Amendment under <U>Section&nbsp;5.2(e)(i)</U>&nbsp;shall
be five (5)&nbsp;Business Days).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT>Each
of the Company and Parent confirms that its respective board of directors (or a duly authorized committee thereof) has approved the contents
and release of an announcement to be made by the Parties in respect of the matters contemplated by this Amendment, in the form agreed
to by or on behalf of the Parties (the &ldquo;<B>Revised Offer Announcement</B>&rdquo;). Following the execution of this Amendment, the
Company and Parent shall jointly, in accordance with, and for the purposes of, the Takeover Rules, procure the release of the Revised
Offer Announcement to a Regulatory Information Service by no later than 5:00 pm, New&nbsp;York City time, on November&nbsp;19, 2025, or
such later time as may be agreed between the Parties in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT>Except
as otherwise expressly provided herein, the Agreement shall remain unchanged and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT>From
and after the execution of this Amendment by the Parties hereto, any reference to the Agreement shall be deemed to be a reference to the
Agreement as amended by this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><U>Sections
10.2</U> through <U>10.7</U> and <U>Sections 10.9</U> through <U>10.16</U> of the Agreement shall apply <I>mutatis mutandis</I> to this
Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
hereto have caused this Amendment to be duly executed and delivered as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ALKERMES PLC, as Parent,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/<FONT STYLE="font-size: 10pt">s/ Declan O&rsquo;Connor</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-size: 10pt">Declan O&rsquo;Connor</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Board Authorized Signatory</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-style: normal; font-weight: normal">[</FONT><I>Signature
Page to Amendment No. 1 to the Transaction Agreement</I><FONT STYLE="font-style: normal; font-weight: normal">]</FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">AVADEL PHARMACEUTICALS PLC, as the
    Company,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Peter Thornton</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-size: 10pt">Peter Thornton</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT>[<I>Signature
Page&nbsp;to Amendment No.&nbsp;1 to the Transaction Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2529228d13_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Alkermes plc Announces Increased Offer to Acquire
Avadel Pharmaceuticals plc</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,&nbsp;IN
WHOLE OR IN PART,&nbsp;IN,&nbsp;INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS
OF SUCH JURISDICTION</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>DUBLIN, November&nbsp;19,
2025</B></FONT> &mdash; Alkermes plc (Nasdaq: ALKS) (&ldquo;<U>Alkermes</U>&rdquo;) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (&ldquo;<U>Avadel</U>&rdquo;)
today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire
Avadel (the &ldquo;<U>Acquisition</U>&rdquo;) for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash
and one (1)&nbsp;non-transferable contingent value right (&ldquo;<U>CVR</U>&rdquo;) entitling holders to a potential additional cash payment
of&nbsp;$1.50&nbsp;per share, contingent upon final U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) LUMRYZ&trade; Approval
(as defined in the form of CVR agreement to be entered into by Alkermes and the rights agent) for the treatment of idiopathic hypersomnia
in adults by the end of 2028 (the &ldquo;<U>Increased Offer</U>&rdquo;).&nbsp;In connection with the Increased Offer, Alkermes and Avadel
have entered into an amendment, dated November&nbsp;18, 2025 (the &ldquo;<U>Amendment</U>&rdquo;), to the definitive transaction agreement
between the parties (the &ldquo;Transaction Agreement&rdquo; and, as amended, the &ldquo;<U>Amended Agreement</U>&rdquo;) previously entered
into and announced on October&nbsp;22, 2025 (the &ldquo;<U>October&nbsp;2.7 Announcement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Increased Offer values Avadel at up to approximately
$2.37 billion, assuming the Milestone Payment (as defined in the revised offer announcement set out below) is made. The transaction, as
revised by the Increased Offer and the Amendment, has been approved by the boards of directors of Alkermes and Avadel and, subject to
the satisfaction of the Conditions (including the extended End Date as described in the revised offer announcement set out below), it
continues to be expected to close in the first quarter of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">On November&nbsp;14,
2025, Avadel announced that it had received an unsolicited proposal from H.&nbsp;Lundbeck A/S (&ldquo;<U>Lundbeck</U>&rdquo; and the &ldquo;<U>Lundbeck
Proposal</U>&rdquo;) to acquire Avadel </FONT><FONT STYLE="background-color: white">and that the Lundbeck Proposal was reasonably expected
to constitute a Company Superior Proposal (as such term is defined in the Transaction Agreement)</FONT>. On November&nbsp;17, 2025, Avadel
further announced that the board of directors of Avadel had determined in good faith, after consultation with its financial and legal
advisors, that the Lundbeck Proposal constituted a &ldquo;Company Superior Proposal&rdquo; for the purposes of the Transaction Agreement.
<FONT STYLE="background-color: white">Following this determination, Alkermes submitted the terms of its proposed Increased Offer to Avadel
on November&nbsp;18, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">After carefully
assessing both the Lundbeck Proposal and Alkermes&rsquo; Increased Offer and revised terms </FONT><FONT STYLE="background-color: white">with
its outside legal counsel and financial advisors</FONT>, the board of directors of Avadel has determined that the Lundbeck Proposal no
longer constitutes a &ldquo;Company Superior Proposal&rdquo; for the purposes of the Transaction Agreement. <FONT STYLE="background-color: white">In
making this determination, the board of directors of Avadel determined that while </FONT>the upfront cash consideration of $21.00 per
share in Alkermes&rsquo; Increased Offer is identical to the cash consideration proposed in the Lundbeck Proposal, the terms of the CVR
in Alkermes&rsquo; Increased Offer are superior to the terms of the CVR included in the Lundbeck Proposal, which was determined to be
unlikely to be achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alkermes and Avadel encourage their respective
shareholders to read the full text of the Amendment to be included with each company&rsquo;s current report on Form&nbsp;8-K, which will
be filed with the United States Securities and Exchange Commission (&ldquo;SEC&rdquo;) in due course and will be made available at https://www.alkermes.com/acquisition.
Further, Avadel intends to file a definitive proxy statement with the SEC related to the Acquisition. Shareholders are urged to read the
definitive proxy statement and such other relevant materials for more information. This summary should be read in conjunction with, and
is subject to, the full text of the revised offer announcement set out below, the Amendment, the Amended Agreement and the definitive
proxy statement (once filed). The Acquisition is subject to the conditions set out in Appendix III to the October&nbsp;2.7 Announcement
(except that the End Date is extended as described in the revised offer announcement set out below) and the further terms set out in the
Amended Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">J.P. Morgan is acting as exclusive financial advisor
to Alkermes, and Paul, Weiss, Rifkind, Wharton&nbsp;&amp; Garrison LLP and McCann FitzGerald LLP are acting as legal counsel to Alkermes
for the transaction. J.P. Morgan has provided fully committed financing to Alkermes in support of the transaction. Cleary Gottlieb Steen&nbsp;&amp;
Hamilton LLP is acting as legal counsel to Alkermes for the financing. Morgan Stanley and Goldman Sachs are acting as financial advisors
to Avadel, and Goodwin Procter LLP and Arthur Cox LLP are acting as legal counsel to Avadel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Alkermes plc</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alkermes plc (Nasdaq: ALKS), a mid-cap growth
and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. Alkermes
has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar
I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and
idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts
and a manufacturing facility in Ohio. For more information, please visit Alkermes&rsquo; website at www.alkermes.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Avadel Pharmaceuticals plc</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a
biopharmaceutical company focused on transforming medicines to transform lives. Avadel&rsquo;s approach includes applying innovative solutions
to the development of medications that address the challenges patients face with current treatment options. Avadel&rsquo;s commercial
product, LUMRYZ&trade;, was approved by the U.S. Food&nbsp;&amp; Drug Administration (FDA) as the first and only once-at-bedtime oxybate
for extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older
with narcolepsy. For more information, please visit Avadel&rsquo;s website at www.avadel.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The release, publication or distribution of this
announcement in or into jurisdictions other than Ireland and the United States may be restricted by Law and therefore any persons who
are subject to the Law of any jurisdiction other than Ireland and the United States should inform themselves about, and observe, any applicable
legal or regulatory requirements. In particular, the ability of persons who are not resident in Ireland or the United States, to vote
their Avadel shares with respect to the Scheme at the Scheme Meeting, or to appoint another person as proxy to vote at the Scheme Meeting
on their behalf, may be affected by the Laws of the relevant jurisdictions in which they are located. Any failure to comply with the applicable
legal or regulatory requirements may constitute a violation of the Laws of any such jurisdiction. To the fullest extent permitted by applicable
Law, the Alkermes and Avadel persons involved in the proposed transaction disclaim any responsibility or liability for the violation of
such restrictions by any person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This announcement has been prepared for the purpose
of complying with the Laws of Ireland and the Irish Takeover Rules, 2022 (the &ldquo;<U>Takeover Rules</U>&rdquo;) and the information
disclosed herein may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with
the Laws of jurisdictions outside of Ireland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Participants in the Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avadel and certain of its directors, executive
officers and employees may be deemed to be participants in the solicitation of proxies from Avadel shareholders in connection with the
transaction and any other matters to be voted on at the Scheme Meeting or the EGM. Information about the directors and executive officers
of Avadel, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in Avadel&rsquo;s
preliminary proxy statement on Schedule 14A for the proposed Acquisition, dated and filed with the SEC on November&nbsp;13, 2025. Other
information regarding the persons who may, under the rules&nbsp;of the SEC, be deemed to be participants in the solicitation of Avadel
shareholders, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the
definitive Proxy Statement (which will contain the Scheme Document) and other relevant materials to be filed with the SEC in connection
with the Acquisition. You may obtain free copies of these documents using the sources indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Offer or Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This announcement is for information purposes
only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation
to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval
in any jurisdiction, pursuant to the transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any
jurisdiction in contravention of applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction will be implemented by means of
a High Court of Ireland sanctioned scheme of arrangement on the terms provided for in the scheme document (or, if the transaction is implemented
by way of a takeover offer, the takeover offer document), which will contain the full terms and conditions of the transaction, including
details of how Avadel&rsquo;s shareholders may vote in respect of the transactions contemplated by the Amended Agreement, including the
Acquisition. Any decision in respect of, or other response to, the proposed transaction, should be made only on the basis of the information
contained in the scheme document (or if the transaction is implemented by way of a takeover offer, the takeover offer document).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Additional Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">In connection with
the proposed Acquisition, Avadel filed with the SEC on November&nbsp;13, 2025 a preliminary Proxy Statement relating to the Scheme Meeting
and the EGM, which includes a draft of the Scheme Document. Avadel intends to file with the SEC a definitive Proxy Statement, which will
be sent to Avadel&rsquo;s shareholders as of the record date(s)&nbsp;to be established for voting at the Scheme Meeting and EGM. This
announcement is not a substitute for the definitive Proxy Statement or any other document that Avadel may file with the SEC or send to
its shareholders in connection with the Acquisition. BEFORE MAKING ANY VOTING DECISION, AVADEL&rsquo;S SHAREHOLDERS ARE URGED TO READ
THE DEFINITIVE PROXY STATEMENT,&nbsp;INCLUDING THE SCHEME DOCUMENT AND ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND OTHER RELEVANT DOCUMENTS
FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED ACQUISITION,&nbsp;INCLUDING ANY DOCUMENTS INCORPORATED BY REFERENCE
IN THE DEFINITIVE PROXY STATEMENT (IF ANY) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Avadel&rsquo;s shareholders will be able to obtain,
without charge, copies of the preliminary and definitive Proxy Statements, including the Scheme Document, and other relevant documents
filed with the SEC (when available) from the SEC&rsquo;s website at </FONT><U>http://www.sec.gov</U> or by directing a written request
to Avadel Pharmaceuticals plc, Ten Earlsfort Terrace, Dublin 2, D02 T380,&nbsp;Ireland, Attention: Investor Relations, from Avadel&rsquo;s
website, <U>www.avadel.com</U> or by contacting Investor Relations via email at investors@avadel.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Responsibility Statement Required by the Takeover
Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Alkermes directors accept responsibility for
the information contained in this announcement other than that relating to Avadel, its Subsidiaries and the Avadel directors and members
of their immediate families, related trusts and persons connected with them but including the Parent Company Statements (for which the
Alkermes directors accept responsibility), and other than the statements made by Avadel in respect of Alkermes (the &ldquo;<U>Company
Parent Statements</U>&rdquo;). To the best of the knowledge and belief of the Alkermes directors (who have taken all reasonable care to
ensure that such is the case), the information contained in this announcement for which they accept responsibility is in accordance with
the facts and does not omit anything likely to affect the import of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Avadel directors accept responsibility for
the information contained in this announcement relating to Avadel and the Avadel directors and members of their immediate families, related
trusts and persons connected with them, except for the statements made by Alkermes in respect of Avadel or its Subsidiaries (the &ldquo;<U>Parent
Company Statements</U>&rdquo;). To the best of the knowledge and belief of the Avadel directors (who have taken all reasonable care to
ensure such is the case), the information contained in this announcement for which they respectively accept responsibility is in accordance
with the facts and does not omit anything likely to affect the import of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Notices Relating to Financial Advisors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">J.P. Morgan Securities LLC, together with its
affiliate J.P. Morgan Securities plc (which is authorized in the United Kingdom by the Prudential Regulation Authority and regulated in
the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (together, &ldquo;<U>J.P. Morgan</U>&rdquo;)
are acting as financial advisor exclusively for Alkermes and no one else in connection with the Acquisition and will not regard any other
person as its client in relation to the Acquisition and will not be responsible to anyone other than Alkermes for providing the protections
afforded to clients of J.P. Morgan or its affiliates, nor for providing advice in relation to the Acquisition or any other matter or arrangement
referred to herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goldman Sachs&nbsp;&amp; Co. LLC, which is authorized
and regulated by the Financial Industry Regulatory Authority, is acting exclusively as financial advisor for Avadel and for no one else
in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters
set out in this announcement and will not be responsible to anyone other than Avadel for providing the protections afforded to clients
of Goldman Sachs&nbsp;&amp; Co. LLC nor for providing advice in relation to the Acquisition or any other matter referred to in this announcement.
Neither Goldman Sachs&nbsp;&amp; Co. LLC nor any of its affiliates (nor their respective directors, officers, employees or agents) owes
or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or
otherwise) to any person who is not a client of Goldman Sachs&nbsp;&amp; Co. LLC in connection with this announcement, any statement contained
herein or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Morgan Stanley&nbsp;&amp; Co. LLC, acting through
its affiliate Morgan Stanley&nbsp;&amp; Co. International plc (together, &ldquo;<U>Morgan Stanley</U>&rdquo;), which is authorized by
the Prudential Regulation Authority and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for
Avadel as financial advisor and for no one else in relation to the matters referred to in this announcement. In connection with such matters,
Morgan Stanley and its directors, officers, employees and agents will not regard any other person as its client, nor will it be responsible
to anyone other than Avadel for providing the protections afforded to their clients or for providing advice in connection with the matters
described in this announcement or any matter referred to herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Disclosure Requirements of the Takeover Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the provisions of Rule&nbsp;8.3(a)&nbsp;of
the Takeover Rules, any person who is &lsquo;interested&rsquo; in (directly or indirectly) 1% or more of any class of &lsquo;relevant
securities&rsquo; of Avadel must make an &lsquo;opening position disclosure&rsquo; following the commencement of the &lsquo;offer period&rsquo;.
An &lsquo;opening position disclosure&rsquo; must contain the details contained in Rule&nbsp;8.6(a)&nbsp;of the Takeover Rules, including,
among other things, details of the person&rsquo;s &lsquo;interests&rsquo; and &lsquo;short positions&rsquo; in any &lsquo;relevant securities&rsquo;
of Avadel. An &lsquo;opening position disclosure&rsquo; by a person to whom Rule&nbsp;8.3(a)&nbsp;applies must be made by no later than
3:30 pm (U.S. Eastern Time) on the day falling ten &lsquo;business days&rsquo; following the commencement of the &lsquo;offer period&rsquo;.
Relevant persons who deal in any &lsquo;relevant securities&rsquo; prior to the deadline for making an &lsquo;opening position disclosure&rsquo;
must instead make a &lsquo;dealing&rsquo; disclosure as described below. The offer period in respect of Avadel in relation to the Acquisition
commenced on October&nbsp;22, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the provisions of Rule&nbsp;8.3(b)&nbsp;of
the Takeover Rules, if any person is, or becomes, &lsquo;interested&rsquo; in (directly or indirectly) 1% or more of any class of &lsquo;relevant
securities&rsquo; of Avadel, that person must publicly disclose all &lsquo;dealings&rsquo; in any &lsquo;relevant securities&rsquo; of
Avadel during the &lsquo;offer period&rsquo;, by no later than 3:30 p.m.&nbsp;(U.S. Eastern Time) on the &lsquo;business day&rsquo; following
the date of the relevant transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If two or more persons cooperate on the basis
of any agreement either express or tacit, either oral or written, to acquire an &lsquo;interest&rsquo; in &lsquo;relevant securities&rsquo;
of Avadel or any securities exchange offeror, they will be deemed to be a single person for the purpose of Rule&nbsp;8.3 of the Takeover
Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, each of Avadel and any offeror must
make an &lsquo;opening position disclosure&rsquo; by no later than 12:00 noon (U.S. Eastern Time) on the date falling ten &lsquo;business
days&rsquo; following the commencement of the &lsquo;offer period&rsquo; or the announcement that first identifies a securities exchange
offeror, as applicable, and disclose details of any &lsquo;dealings&rsquo; by it or any person &lsquo;acting in concert&rsquo; with it
in &lsquo;relevant securities&rsquo; during the &lsquo;offer period&rsquo;, by no later than 12:00 noon (U.S. Eastern Time) on the business
day following the date of the transaction (see Rules&nbsp;8.1, 8.2 and 8.4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A disclosure table, giving details of the companies
in whose &lsquo;relevant securities&rsquo; &lsquo;opening position&rsquo; and &lsquo;dealings&rsquo; should be disclosed can be found
on the Irish Takeover Panel&rsquo;s website at www.irishtakeoverpanel.ie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Interests&rdquo; in securities arise, in
summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular,
a person will be treated as having an &lsquo;interest&rsquo; by virtue of the ownership or control of securities, or by virtue of any
option in respect of, or derivative referenced to, securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Terms in quotation marks in this section are defined
in the Takeover Rules, which can be found on the Irish Takeover Panel&rsquo;s website. If you are in any doubt as to whether or not you
are required to disclose an &lsquo;opening position&rsquo; or &lsquo;dealing&rsquo; under Rule&nbsp;8, please consult the Irish Takeover
Panel&rsquo;s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Profit Forecast / Quantified Financial Benefit
Statement / Asset Valuations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No statement in this revised offer announcement
is intended to constitute a profit forecast, profit estimate or quantified financial benefit statement for any period, nor should any
statements be interpreted to mean that earnings or earnings per share will, for the current or future financial years or other periods,
necessarily be greater or lesser than those for the relevant preceding financial periods for Alkermes or Avadel. No statement in this
revised offer announcement constitutes an asset valuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Publication on Website</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Rule&nbsp;26.1 of the Takeover
Rules, a copy of this revised offer announcement will be available on Avadel&rsquo;s website at www.avadel.com and on Alkermes&rsquo;
website at www.alkermes.com by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication of this revised
offer announcement. Neither the content of any such websites referred to in this revised offer announcement nor the content of any other
websites accessible from hyperlinks on such websites is incorporated into, or forms part of, this revised offer announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Right to Switch to a Takeover Offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alkermes reserves the right to elect to implement
the Acquisition by way of a Takeover Offer for the entire issued and to be issued ordinary share capital of Avadel as an alternative to
the Scheme, subject to the provisions of the Takeover Rules&nbsp;and the Amended Agreement and with the Irish Takeover Panel&rsquo;s consent,
whether or not the Scheme Document has been posted. In such event, the Acquisition would be implemented on the same terms (subject to
appropriate amendments, including without limitation an acceptance condition set at 80% of the shares to which such offer relates, or
such lesser percentage being more than 50%, as Parent may, with the consent of the Panel (if required) decide) so far as are applicable,
as those which would apply to the Scheme and subject to the amendments referred to in Appendix III to the October&nbsp;2.7 Announcement
and in the Amended Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Alkermes exercises its right to implement the
Acquisition by way of a Takeover Offer as an alternative to the Scheme, subject to the provisions of the Takeover Rules&nbsp;and the Amended
Agreement and with the Irish Takeover Panel&rsquo;s consent, such offer would be made in compliance with applicable U.S. Laws and regulations,
including the registration requirements of the Securities Act and the tender offer rules&nbsp;under the Exchange Act and any applicable
exemptions provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Certain statements
set forth in this announcement constitute &ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, but not limited to, statements concerning: the expected terms and timelines of Alkermes&rsquo;
planned acquisition of Avadel, including Alkermes&rsquo; recommended cash and CVR offer for Avadel and the expected value of such offer
and its consummation; Alkermes&rsquo; expectations concerning its and the potential combined organization&rsquo;s future financial and
operating performance, business plans or prospects, including estimates, forecasts, targets and plans for LUMRYZ&trade;, and Alkermes&rsquo;
expectations regarding development plans, activities and timelines for, and the potential therapeutic and commercial value of, its and
the combined organization&rsquo;s portfolio of development candidates. Alkermes cautions that forward-looking statements are inherently
uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty
and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to
various risks and uncertainties. These risks and uncertainties include, among others: whether the planned acquisition will be pursued
or consummated on the anticipated timelines or at all; whether the regulatory approvals, shareholder approvals or other conditions necessary
for consummation of the planned acquisition will be obtained, satisfied or waived, as applicable, on the anticipated timelines or at all;
even if the acquisition is consummated, the businesses of Alkermes and Avadel may not be effectively integrated and the expected benefits
and value of the acquisition may not be achieved; there may be significant changes in transaction costs and/or unknown or inestimable
liabilities and potential litigation associated with the planned acquisition; whether any general economic, political, market and business
conditions, or future exchange and interest rates, changes in tax laws, regulations, rates and policies, may have a negative impact on
Alkermes, Avadel or the combined organization following consummation of the planned acquisition; the announcement or pendency of the planned
acquisition could result in disruption to the business and make it more difficult to maintain business and operational relationships of
Alkermes and Avadel, including the ability of each of Alkermes and Avadel to attract and retain highly qualified management and other
clinical and scientific personnel; the possibility that competing offers may be made for Avadel; clinical development activities may not
be initiated or completed on expected timelines or at all; the results of development activities may not be positive, or predictive of
future results from such activities, results of future development activities or real-world results; Alkermes&rsquo; or Avadel&rsquo;s
products or product candidates could be shown to be ineffective or unsafe; the FDA or regulatory authorities outside the&nbsp;U.S.&nbsp;may
not agree with Alkermes&rsquo; or Avadel&rsquo;s regulatory approval strategies or may make adverse decisions regarding its products;
Alkermes or Avadel may not be able to continue to successfully commercialize their products or support revenue growth from such products;
there may be a reduction in payment rate or reimbursement for the Alkermes&rsquo; or Avadel&rsquo;s products or an increase in related
financial obligations to government payers; Alkermes and Avadel&rsquo;s products may prove difficult to manufacture, be precluded from
commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse;
and those risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo; in Alkermes&rsquo; Annual Report on Form&nbsp;10-K
for the year ended Dec.&nbsp;31, 2024 and in subsequent filings made by Alkermes with the U.S. Securities and Exchange Commission (SEC),
which are available on the SEC&rsquo;s website at </FONT>www.sec.gov. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Alkermes and/or the members
of its board of directors disclaim any intention or responsibility for updating or revising any forward-looking statements contained in
this announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LUMRYZ&trade; is a trademark of Flamel Ireland Limited, a subsidiary
of Avadel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rounding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain figures included in this revised offer
announcement have been subjected to rounding adjustments. Accordingly, any figures shown for the same category presented in different
tables may vary slightly and figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that precede
them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overseas Jurisdictions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The release, publication or distribution of this
revised offer announcement in or into jurisdictions other than Ireland and the United States may be restricted by Law and therefore any
persons who are subject to the Law of any jurisdiction other than Ireland and the United States should inform themselves about, and observe,
any applicable legal or regulatory requirements. In particular the ability of persons who are not resident in Ireland or the United States,
to vote their Company Shares with respect to the Scheme at the Scheme Meeting, or to appoint another person as proxy to vote at the Scheme
Meeting on their behalf, may be affected by the Laws of the relevant jurisdictions in which they are located. Any failure to comply with
the applicable legal or regulatory requirements may constitute a violation of the Laws of any such jurisdiction. To the fullest extent
permitted by applicable Law, the Company, the Parent and persons involved in the Acquisition disclaim any responsibility or liability
for the violation of such restrictions by any person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This announcement has been prepared for the purpose
of complying with the Laws of Ireland and the Takeover Rules&nbsp;and the information disclosed may not be the same as that which would
have been disclosed if this announcement had been prepared in accordance with the Laws of jurisdictions outside of Ireland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise determined by Parent or required
by the Takeover Rules, and permitted by applicable Law and regulation, the Acquisition will not be made available directly or indirectly,
in, into or from any Restricted Jurisdiction and no person may vote in favor of the Acquisition by any use, means, instrumentality or
facilities from within a Restricted Jurisdiction or any other jurisdiction if to do so would constitute a violation of the Laws of that
jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further details in relation to overseas shareholders
will be contained in the definitive Proxy Statement (which will include the Scheme Document).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCREASED RECOMMENDED CASH AND CONTINGENT VALUE
RIGHT OFFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>for</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AVADEL PHARMACEUTICALS PLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>by</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALKERMES PLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>to be implemented by way of a scheme of arrangement
under Chapter 1 of Part&nbsp;9 of the Companies Act 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD><B>Introduction</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&nbsp;22, 2025,
the board of directors of Alkermes plc (&ldquo;<U>Alkermes</U>&rdquo; or &ldquo;<U>Parent</U>&rdquo;) (Nasdaq: ALKS) and Avadel Pharmaceuticals
plc (&ldquo;<U>Avadel</U>&rdquo; or the &ldquo;<U>Company</U>&rdquo;) (Nasdaq: AVDL) announced that they had entered into a definitive
agreement (the &ldquo;<U>October&nbsp;2.7 Announcement</U>&rdquo;), pursuant to which Alkermes would, subject to the satisfaction of the
Conditions (including approval by the Company Shareholders and the High Court) acquire the entire issued and to be issued ordinary share
capital of the Company for $18.50 in cash and one (1)&nbsp;non-tradeable contingent value right (&ldquo;<U>CVR</U>&rdquo;) representing
a right to receive an additional $1.50 in cash per Company Share, subject to the achievement of the Milestone (as described in the October&nbsp;2.7
Announcement) (the &ldquo;<U>Original Offer</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alkermes continues to believe
that there is a compelling strategic and financial rationale for undertaking the Acquisition (as defined below), and Avadel continues
to believe Alkermes has the capacity to maximize the value of Avadel&rsquo;s current portfolio. The board of directors of Alkermes (the
 &ldquo;<U>Alkermes Board</U>&rdquo;) and the board of directors of Avadel (the &ldquo;<U>Company Board</U>&rdquo;) are pleased to announce
that they have reached agreement on the terms of an increased recommended offer for Alkermes to acquire the entire issued and to be issued
ordinary share capital of Avadel (the &ldquo;<U>Acquisition</U>&rdquo;) for consideration consisting of $21.00 in cash per Company Share
and one (1)&nbsp;non-tradeable contingent value right (&ldquo;<U>CVR</U>&rdquo;) representing a right to receive an additional $1.50 in
cash per Company Share, subject to the achievement of the Milestone (the &ldquo;<U>Increased Offer</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is intended that the Acquisition
will be effected by means of a High Court-sanctioned &ldquo;scheme of arrangement&rdquo; in accordance with Chapter 1 of Part&nbsp;9 of
the Act pursuant to which Alkermes will acquire all of the outstanding Company Shares in exchange for the Consideration (although Alkermes
reserves the right to effect the Acquisition by way of a Takeover Offer, subject to the terms of the Transaction Agreement (as amended
by Amendment No.&nbsp;1 to the Transaction Agreement), compliance with the Takeover Rules&nbsp;and with the consent of the&nbsp;Irish
Takeover Panel). The Acquisition will be subject to the Conditions set out in Appendix III to the October&nbsp;2.7 Announcement (except
that the End Date is extended as described herein). Except as otherwise defined herein, capitalized terms used but not defined in this
revised offer announcement have the same meanings given to them in the October&nbsp;2.7 Announcement. This revised offer announcement
should be read in conjunction with the full text of the October&nbsp;2.7 Announcement (including the appendices to the October&nbsp;2.7
Announcement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board has determined
that the Acquisition by Alkermes is in the best interests of all Company Shareholders and has approved the Acquisition on the terms set
out in the Increased Offer. The Acquisition and the Increased Offer have also been approved by the board of directors of Alkermes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD><B>Increased Offer</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the Increased
Offer, subject to satisfaction of the Conditions (including the extended End Date as described herein), at Completion each Company Shareholder
will be entitled to receive for each Company Share held at the Scheme Record Time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>$21.00
in cash (the &ldquo;</B></FONT><B><U>Cash Consideration</U>&rdquo;); and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>One
(1)&nbsp;non-tradeable CVR, representing a contractual right to receive a future conditional payment of $1.50, settleable in cash (a &ldquo;</B></FONT><B><U>Milestone
Payment</U>&rdquo;), upon the achievement of the Milestone prior to 11:59 p.m., U.S. Eastern Time on December&nbsp;31, 2028 (&ldquo;<U>Milestone
Expiration</U>&rdquo;).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the CVRs remain
as set out in the October&nbsp;2.7 Announcement, and will be subject to the terms and conditions set forth in the Contingent Value Rights
Agreement to be entered into by and between Alkermes and the rights agent, substantially in the form as appended as Exhibit&nbsp;A to
the Transaction Agreement (the &ldquo;<U>CVR Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no certainty that
the Milestone will occur, that the Milestone will occur prior to the Milestone Expiration, or that any payment will be made pursuant to
the CVRs. If the Milestone does not occur prior to the Milestone Expiration, the amount payable pursuant to the CVR Agreement will be
zero. A summary of the terms of the CVRs is contained in the October&nbsp;2.7 Announcement and further details will be contained in the
definitive Proxy Statement (which will include the Scheme Document) once filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming the Milestone Payment
is made, the Increased Offer values the entire issued and to be issued ordinary share capital of the Company at approximately $2.37 billion
on a fully diluted basis calculated using the Treasury Stock Method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sources and bases of information
contained in this revised offer announcement to calculate the implied value of the Increased Offer are set out in Appendix I (Sources
and Bases of Information) to this revised offer announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Save as described in this
revised offer announcement, the Increased Offer will be on the same terms and conditions as set out in the October&nbsp;2.7 Announcement
(except that the End Date is extended as described herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD><TD><B>Avadel Background to and Reasons for Recommending the Revised Offer</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As set out in more detail
in the October&nbsp;2.7 Announcement, on October&nbsp;22, 2025, following a period of negotiation, Avadel and Alkermes executed the Transaction
Agreement. Prior to the opening of trading on Nasdaq and the New York Stock Exchange, Avadel and Alkermes issued the October&nbsp;2.7
Announcement announcing the Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November&nbsp;13, 2025,
Avadel received the Lundbeck Proposal under which H Lundbeck A/S (&ldquo;<U>Lundbeck</U>&rdquo;) proposed to acquire Avadel for up to
$23.00 per Company Share, consisting of (i)&nbsp;$21.00 in cash per Company Share, plus (ii)&nbsp;one non-tradeable CVR representing the
right to receive up to $2.00 in cash as follows: (a)&nbsp;$1.00 per Company Share in cash upon LUMRYZ&trade; reaching annual net sales
globally of at least $450 million in any calendar year by December&nbsp;31, 2027, and (b)&nbsp;$1.00 per Company Share in cash upon LUMRYZ&trade;
reaching annual net sales globally of at least $700 million in any calendar year by December&nbsp;31, 2030. Later that evening, Avadel
sent a copy of the Lundbeck Proposal to Alkermes in accordance with the requirements of the Transaction Agreement and the Company Board
convened and determined the Lundbeck Proposal was reasonably expected to result in a &ldquo;Company Superior Proposal&rdquo; as defined
in, and for the purposes of, the Transaction Agreement. On November&nbsp;14, 2025, Avadel announced details of the Lundbeck Proposal and
the Company Board&rsquo;s determination that the Lundbeck Proposal was reasonably expected to result in a &ldquo;Company Superior Proposal.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As announced on November&nbsp;17,
2025, on November&nbsp;16, 2025, the Company Board convened and determined in good faith, after consultation with its financial and legal
advisors, that the Lundbeck Proposal constituted a &ldquo;Company Superior Proposal&rdquo; as defined in and for the purposes of the Transaction
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November&nbsp;18, 2025,
Avadel received the Increased Offer from Alkermes. The Company Board convened later that day and carefully assessed both the Lundbeck
Proposal and Alkermes&rsquo; Increased Offer together with its financial and legal advisors. Following this assessment, the Company Board
determined that while the upfront cash consideration of $21.00 per Company Share in Alkermes&rsquo; Increased Offer is identical to the
cash consideration proposed in the Lundbeck Proposal, the terms of the CVR in Alkermes&rsquo; Increased Offer are superior to the terms
of the CVR included in the Lundbeck Proposal, which was determined to be unlikely to be achieved. As a result, the Company Board determined
that the Lundbeck Proposal no longer constituted a &ldquo;Company Superior Proposal&rdquo; for the purposes of the Transaction Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Board carefully
considered the terms of the Increased Offer, consulted with Avadel senior management and representatives of its financial and legal advisors,
and considered a number of factors, each of which was supportive of its decision to approve the Increased Offer and of its resolution
to recommend the Increased Offer to the Company Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company believes Alkermes
has the capacity to maximize the value of the Company&rsquo;s current portfolio and accelerate the ability for LUMRYZ&trade; to reach
more patients globally with increased global commercial scale as well as enhanced R&amp;D and technology capabilities to rapidly advance
the pipeline to develop more therapies for patients who are underserved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further detail in respect
of the background and reasons for recommending the Acquisition will be included in the definitive Proxy Statement (which will include
the Scheme Document).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD><B>Company Board Recommendation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Having taken into account
the relevant factors, applicable risks and alternatives available to the Company, the Company Board, which has been so advised as to the
financial terms of the Acquisition by Morgan Stanley&nbsp;&amp; Co. LLC (&ldquo;<U>Morgan Stanley</U>&rdquo;) and Goldman Sachs&nbsp;&amp;
Co. LLC (&ldquo;<U>Goldman Sachs</U>&rdquo;), as financial advisors and Rule&nbsp;3 advisors to the Company, considers the terms of the
Acquisition (as revised by the Increased Offer) to be fair and reasonable. In providing their advice to the Company Board, Morgan Stanley
and Goldman Sachs have taken into account the commercial assessments of the Company Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, the Company Board
intends to unanimously recommend to the Company Shareholders to vote in favor of the Scheme Meeting Resolution and the Required EGM Resolutions
or, if the Acquisition is implemented by way of a Takeover Offer, to accept or procure acceptance of such Takeover Offer, as the members
of the Company Board who hold Company Shares and equity awards in respect of Company Shares intend to do in respect of their own beneficial
holdings of, in the aggregate, 4,398,016 Company Shares as of the date of this revised offer announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.</B></TD><TD><B>The Scheme Process</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It continues to be intended
that the Acquisition will be effected by means of a High Court sanctioned &ldquo;scheme of arrangement&rdquo; in accordance with Chapter
1 of Part&nbsp;9 of the Act pursuant to which Alkermes will acquire all of the outstanding Company Shares in exchange for the Consideration.
The Acquisition will be subject to the Conditions set out in Appendix III to the October&nbsp;2.7 Announcement (except that the End Date
is amended as described herein) and to be set forth in the Scheme described in the Scheme Document which will be delivered to Company
Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is expected that the definitive
Proxy Statement (which will contain the Scheme Document), containing further information about the Acquisition, the expected timetable
for completion of the Acquisition, action to be taken by Company Shareholders and notices of the Scheme Meeting and the EGM, will be published
as soon as reasonably practicable after this revised offer announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to satisfaction or
waiver (as applicable) of the Conditions, the Acquisition is expected to be completed in the first quarter of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Scheme does not become
effective on or before the End Date, it will lapse and the Acquisition will not proceed (unless the Company and Alkermes otherwise agree
and the Irish Takeover Panel otherwise consents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.</B></TD><TD><B>Transaction Agreement Amendment</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and Alkermes have
entered into Amendment No.&nbsp;1 to the Transaction Agreement, dated November&nbsp;18, 2025, as modified to reflect the terms of the
Increased Offer, and to make other consequential amendments and updates to reflect the Acquisition. In particular:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the End Date is extended from nine months to
twelve months and, depending on the occurrence of certain circumstances, to fifteen months<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT>;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Alkermes agrees to promptly take the steps necessary
to obtain all Clearances under the HSR Act and each other Antitrust Law so as to enable the parties to consummate the Acquisition as promptly
as reasonably practicable and in any event on or before the End Date, including, to the extent necessary to obtain such Clearances, (i)&nbsp;committing
to or effecting, by consent decree, hold separate orders, trust, or otherwise, the sale, divestiture, license, transfer, assignment or
other disposition of assets or businesses of Alkermes, its Subsidiaries or Affiliates or the Company, or any portions thereof, (ii)&nbsp;terminating,
relinquishing, modifying, transferring, assigning, restructuring or waiving existing agreements, collaborations, relationships, ventures,
contractual rights, obligations or other arrangements of Alkermes, its Subsidiaries or Affiliates or the Company, (iii)&nbsp;creating
or consenting to create any relationships, ventures, contractual rights, obligations, behavioral undertakings or other arrangements of
Alkermes, its Subsidiaries or Affiliates or the Company (or, in each case, agreeing or offering to agree to do the same) and (iv)&nbsp;contesting
any Action brought by any Governmental Entity or other Person challenging or seeking to enjoin, prevent or delay the closing of the Acquisition;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Alkermes agrees not to acquire or agree to acquire
a substantial portion of the assets or equity interests in any Person, or otherwise acquire any assets, if such action would reasonably
be expected to (i)&nbsp;impose a material delay in obtaining, or significantly increase the risk of not obtaining, any consents of any
Governmental Entity necessary to consummate the Acquisition or the expiration or termination of any applicable waiting period, (ii)&nbsp;materially
increase the risk of any Governmental Entity entering an order prohibiting the consummation of the Acquisition or (iii)&nbsp;materially
delay the closing of the Acquisition;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the obligations of the Company with respect to
financing cooperation are deleted in their entirety; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the maximum reimbursement payable by the Company
to Alkermes if the Transaction Agreement (as amended by Amendment No.&nbsp;1 to the Transaction Agreement) is terminated in certain circumstances,
including a Change of Recommendation Termination or a Superior Proposal Termination (each, as defined in the Amended Agreement, and further
detailed in the October&nbsp;2.7 Announcement and the Scheme Document), is increased from $19.3 million (being 1% of the aggregate value
of the total Cash Consideration payable with respect to Company Shares under the Original Offer) to $22.1 million (being 1% of the aggregate
value of the total Cash Consideration payable with respect to Company Shares under the Increased Offer).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">The revised definition of the End Date being as follows: &ldquo;&ldquo;<B>End
Date</B>&rdquo; means the date that is twelve (12) months from the date of this Agreement, provided, that if the Completion shall not
have occurred as of the End Date and all the conditions to Completion, other than Conditions 1, 2.3, 2.4 and 3.1 (including as a result
of a Government Shutdown), would be satisfied if the Completion were to occur on such date, the End Date shall be automatically extended
to the date that is fifteen months (15) from the date of this Agreement, and such date shall be the End Date.&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Goldman Sachs and Morgan Stanley,
as Rule&nbsp;3 advisors to the Company, and the Company have confirmed in writing to the Irish Takeover Panel that, in the opinion of
Goldman Sachs, Morgan Stanley and the Company (respectively), in the context of the note to Rule&nbsp;21.2 of the Takeover Rules&nbsp;and
the Acquisition, the Expenses Reimbursement Provisions (as amended by Amendment No.&nbsp;1 to the Transaction Agreement) are in the best
interests of the Company Shareholders. The Irish Takeover Panel has consented to the Company entering into the Expenses Reimbursement
Provisions (as amended by Amendment No.&nbsp;1 to the Transaction Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>7.</B></TD><TD><B>Company Share Plans</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Rule&nbsp;15
of the Takeover Rules, Alkermes will make appropriate proposals to participants of the Company Share Plans in relation to the options
and awards under the Company Share Plans, which will reflect the terms of the Increased Offer. Participants will be contacted separately,
at or as soon as possible after the time of publication of the Scheme Document, regarding the effect of the Acquisition on their options
and awards under the Company Share Plans and the relevant details will be summarized in the Scheme Document. The Scheme will extend to
any Company Shares which are unconditionally allotted or issued at or before the Effective Time, including those allotted or issued to
satisfy the exercise of options or vesting of awards under the Company Share Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>8.</B></TD><TD><B>Financing the Increased Offer</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alkermes has secured fully
underwritten financing commitments from JPMorgan Chase Bank, N.A., for an aggregate amount of approximately $1.5 billion, to finance,
together with Alkermes&rsquo; own cash resources, the Acquisition (as revised by the Increased Offer). Further information on the financing
of the Acquisition will be set out in the Scheme Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">J.P. Morgan Securities plc,
in its capacity as financial advisor to Alkermes, is satisfied that sufficient resources are available to Alkermes to enable it to satisfy
in full the Cash Consideration payable to Company Shareholders under the terms of the Acquisition (as revised by the Increased Offer).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No cash confirmation exercise
has been undertaken by Alkermes to verify that sufficient resources will be available to it to satisfy any payments that may become due
in respect of the CVRs. J.P. Morgan Securities plc, as financial advisor to Alkermes, has not been required to confirm, and has not confirmed,
that sufficient resources are available to Alkermes to satisfy any payments that may become due in respect of the CVRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>9.</B></TD><TD><B>Disclosure of Interests in Relevant Securities of the Company</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Save as disclosed in the opening
position disclosure made by Alkermes on November&nbsp;5, 2025, as at the close of business on November&nbsp;18, 2025 (being the last Business
Day prior to the release of this revised offer announcement), none of Alkermes or, so far as Alkermes is aware, any person Acting in Concert
with Alkermes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>had an interest in relevant securities of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>had any short position in relevant securities of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>had received an irrevocable commitment or letter of intent to accept the terms of the Acquisition in respect of relevant securities
of Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>had borrowed or lent any Company Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, no arrangement
to which Rule&nbsp;8.7 of the Takeover Rules&nbsp;applies exists between Alkermes or the Company or a person Acting in Concert with Alkermes
or the Company in relation to Company Shares. For these purposes, an &ldquo;arrangement to which Rule&nbsp;8.7 of the Takeover Rules&nbsp;applies&rdquo;
includes any indemnity or option arrangement, and any agreement or understanding, formal or informal, of whatever nature, between two
or more persons relating to relevant securities which is or may be an inducement to one or more of such persons to deal or refrain from
dealing in such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>10.</B></TD><TD><B>Update on Proxy Statement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule&nbsp;24.1(b)&nbsp;as
amended by Section&nbsp;3(7)&nbsp;of Appendix 4 of the Takeover Rules, requires that, except with the consent of the Panel, and subject
to Rule&nbsp;2.11 of the Takeover Rules, the Company must send the Scheme Document to Company Shareholders within 28 days of the announcement
of a firm intention to make an offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&nbsp;19, 2025,
the Panel agreed to grant its consent to a derogation from Rule&nbsp;24.1(b)&nbsp;as amended by Section&nbsp;3(7)&nbsp;of Appendix 4 of
the Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preliminary Proxy Statement
(which included a draft of the Scheme Document) was filed by the Company on November&nbsp;13, 2025. The preparation of the definitive
Proxy Statement may take more than 28 days from the date of the announcement of a firm intention to make an offer. Also, the SEC may elect
to review the preliminary Proxy Statement. This review process may take 10 days or longer to complete. Under SEC rules, the definitive
Proxy Statement may not be mailed to Company Shareholders until such review is complete (such review to be deemed complete if the SEC
has not affirmatively notified the Company on or prior to the tenth (10<SUP>th</SUP>) calendar day after filing the preliminary Proxy
Statement of any comments or intent to review the Proxy Statement). The Panel granted the derogation on the basis that the Scheme Document
cannot be sent until the SEC&rsquo;s review of the Proxy Statement is completed. The Proxy Statement (which will also contain the Scheme
Document) will be mailed to Company Shareholders as soon as practicable after a definitive Proxy Statement is filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>11.</B></TD><TD><B>Rule&nbsp;2.7(b)(xv)&nbsp;Statement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the Transaction
Agreement (as amended by Amendment No.&nbsp;1 to the Transaction Agreement), Alkermes will have the right to reduce the Increased Offer
by the amount of any dividend (or other distribution) which is paid or becomes payable by the Company to Company Shareholders after the
date of this revised offer announcement but prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>12.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Transaction Agreement
and Amendment No.&nbsp;1 to the Transaction Agreement are governed by the Laws of the State of Delaware. However, the Acquisition and
the Scheme, and matters related thereto (including matters related to the Takeover Rules), shall, to the extent required by the Laws of
Ireland, be governed by, and construed in accordance with, the Laws of Ireland. The interpretation of the duties of the Company Directors
shall also be governed by, and construed in accordance with, the Laws of Ireland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Goldman Sachs, Morgan Stanley
and J.P. Morgan have each given and not withdrawn their consent to the publication of this revised offer announcement with the inclusion
herein of the references to their names in the form and context in which they appear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Acquisition is subject
to,&nbsp;<I>inter alia</I>, the terms and conditions of the Transaction Agreement (as amended by Amendment No.&nbsp;1 to the Transaction
Agreement) and the terms and the satisfaction or waiver (as applicable) of the Conditions set out in Appendix III (<I>Conditions of the
Acquisition and the Scheme)</I> to the October&nbsp;2.7 Announcement (except that the End Date is extended as described herein). The Acquisition
is also subject to the full terms and conditions which will be set out in the Scheme Document. The CVRs are further subject to the terms
and conditions of the CVR Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Appendix I (<I>Sources and
Bases of Information</I>) contains further details of the sources of information and bases of calculations set out in this revised offer
announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Be aware that addresses, electronic
addresses and certain other information provided by Company Shareholders, holders of Alkermes ordinary shares, persons with information
rights and other relevant persons for the receipt of communications from the Company, and/or Alkermes may be exchanged between the Parties
as required by the Takeover Rules&nbsp;and applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This revised offer announcement
does not constitute a prospectus or a prospectus equivalent document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any response in relation to
the Acquisition should be made only on the basis of the information contained in the Scheme Document and the Proxy Statement or any document
by which the Acquisition and the Scheme are made. Company Shareholders are advised to read carefully the formal documentation in relation
to the Acquisition, including the Scheme Document once the Proxy Statement has been sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are in any doubt about
the contents of this revised offer announcement or the action you should take, you are recommended to seek your own independent financial
advice immediately from your appropriately authorized independent financial advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENQUIRIES</B></FONT></TD>
<TD STYLE="vertical-align: bottom; width: 50%">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alkermes</B></FONT></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">: Katie Joyce </FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +1 781 249 8927</FONT></TD></TR>

<TR>
<TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">: Sandy Coombs </FONT></TD>
<TD STYLE="vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +1 781 609 6377</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>J.P. Morgan<BR> (exclusive financial advisor to Parent)</B></FONT></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><P STYLE="margin-top: 0; margin-bottom: 0">Jeremy Meilman / Andy Ham</P>
                                <P STYLE="margin-top: 0; margin-bottom: 0">Dwayne Lysaght / Edward Hatter</P></TD>
<TD STYLE="vertical-align: bottom"><P STYLE="margin-top: 0; margin-bottom: 0">Tel: +1 212 270 6000</P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0">Tel: +44 203 493 8000</P></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Avadel</B></FONT></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">: Alyssa Ramirez (Real Chemistry)</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +1 212 301 7200</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">: Austin Murtagh (Precision AQ)</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +1 212 698-8696</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><B>Morgan Stanley</B></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><P STYLE="margin-top: 0; margin-bottom: 0">Tedd Smith / Daniel Cohen</P>
    <P STYLE="margin-top: 0; margin-bottom: 0">David Kitterick / Ben Nassau </P></TD>
<TD>Tel: +1 212 761 4000 &nbsp; &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><B>Goldman Sachs</B></TD>
<TD STYLE="vertical-align: bottom"></TD></TR>
<TR>
<TD STYLE="vertical-align: top"><P STYLE="margin-top: 0; margin-bottom: 0"> Peter van der Goes / Ryan Fisk / Emily West</P>
                                <P STYLE="margin-top: 0; margin-bottom: 0">Warren Stables</P></TD>
<TD STYLE="vertical-align: bottom"><P STYLE="margin-top: 0; margin-bottom: 0">Tel: +1 212 902 1000</P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0">Tel: +44 207 774 1000</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Paul, Weiss, Rifkind, Wharton&nbsp;&amp; Garrison
LLP and McCann FitzGerald LLP are acting as legal advisors to Alkermes and no one else in connection with the matters set out in this
revised offer announcement. Goodwin Procter LLP and Arthur Cox LLP are acting as legal advisors to the Company and no one else in connection
with the matters set out in this revised offer announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>12.1</B></TD><TD><B>NO OFFER OR SOLICITATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This revised offer announcement
is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation
of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation
of any vote or approval in any jurisdiction, pursuant to the Acquisition or otherwise, nor shall there be any sale, issuance or transfer
of securities in any jurisdiction in contravention of applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Acquisition will be implemented
by means of a High Court-sanctioned scheme of arrangement on the terms provided for in the Scheme Document (or, if the Acquisition is
implemented by way of a Takeover Offer, the Takeover Offer Document), which will contain the full terms and conditions of the Acquisition,
including details of how Company Shareholders may vote in respect of the Acquisition. Any decision in respect of, or other response to,
the Acquisition, should be made only on the basis of the information contained in the Scheme Document (or if the Acquisition is implemented
by way of a Takeover Offer, the Takeover Offer Document).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>12.2</B></TD><TD><B>IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the proposed
Acquisition, the Company filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on November&nbsp;13, 2025 a preliminary
Proxy Statement relating to the Scheme Meeting and the EGM, which includes a draft of the Scheme Document. The definitive Proxy Statement
will be mailed to Company Shareholders as of the record date(s)&nbsp;to be established for voting at the Scheme Meeting and EGM. This
revised offer announcement is not a substitute for the Proxy Statement or any other document that the Company may file with the SEC or
send to its shareholders in connection with the Acquisition. BEFORE MAKING ANY VOTING DECISION, THE COMPANY&rsquo;S SHAREHOLDERS ARE URGED
TO READ THE DEFINITIVE PROXY STATEMENT,&nbsp;INCLUDING THE SCHEME DOCUMENT AND ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND OTHER RELEVANT
DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED ACQUISITION,&nbsp;INCLUDING ANY DOCUMENTS INCORPORATED BY
REFERENCE IN THE DEFINITIVE PROXY STATEMENT (IF ANY) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES TO THE PROPOSED ACQUISITION. The Company Shareholders will be able
to obtain, without charge, copies of the preliminary and definitive Proxy Statements, including the Scheme Document, and other relevant
documents filed with the SEC (as and when available) from the SEC&rsquo;s website at http://www.sec.gov or by directing a written request
to 16640 Chesterfield Grove Road #200, Chesterfield, MO 63005, United States, Attention: Investor Relations, or from Avadel&rsquo;s website,
www.avadel.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any vote in respect of the
Scheme Meeting Resolution or the EGM Resolutions to approve the Acquisition, the Scheme or related matters, or other responses in relation
to the Acquisition, should be made only on the basis of the information contained in the definitive Proxy Statement (including the Scheme
Document).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>12.3</B></TD><TD><B>PARTICIPANTS IN THE SOLICITATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and certain of
its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from Company Shareholders
in connection with the Acquisition and any other matters to be voted on at the Scheme Meeting or the EGM. Information about the directors
and executive officers of the Company, including a description of their direct or indirect interests, by security holdings or otherwise,
is set forth in the Company&rsquo;s preliminary proxy statement on Schedule 14A for the proposed Acquisition, filed with the SEC on November&nbsp;13,
2025. Other information regarding the persons who may, under the rules&nbsp;of the SEC, be deemed to be participants in the solicitation
of Company Shareholders, including a description of their direct or indirect interests, by security holdings or otherwise, will be set
forth in the Proxy Statement (which will contain the Scheme Document) and other relevant materials to be filed with the SEC in connection
with the Acquisition. You may obtain free copies of these documents using the sources indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.4</B></FONT></TD><TD><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Certain
statements set forth in this revised offer announcement constitute &ldquo;forward-looking statements&rdquo; within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical facts included in this
revised offer announcement may be forward-looking statements. Without limitation, forward-looking statements often include words such
as &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;outlook,&rdquo; &ldquo;could,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo; &ldquo;should,&rdquo; &ldquo;may,&rdquo;
 &ldquo;assume&rdquo; and &ldquo;continue&rdquo; as well as variations of such words and similar expressions are intended to identify
such forward-looking statements. Such statements include, but are not limited to, statements concerning: the expected terms and timelines
of Alkermes&rsquo; planned acquisition of Avadel, including statements concerning Alkermes&rsquo; recommended cash and CVR offer for
Avadel and the expected value of such offer and its consummation; Alkermes&rsquo; expectations concerning its and the potential combined
organization&rsquo;s future financial and operating performance, business plans or prospects, including estimates, forecasts, targets
and plans for LUMRYZ<SUP>TM</SUP>, and Alkermes&rsquo; expectations regarding development plans, activities and timelines for, and the
potential therapeutic and commercial value of, its and the combined organization&rsquo;s portfolio of development candidates. Alkermes
cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees
and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from
those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include,
among others: whether the planned acquisition will be pursued or consummated on the anticipated timelines or at all; whether the regulatory
approvals, shareholder approvals or other conditions necessary for consummation of the planned acquisition will be obtained, satisfied
or waived, as applicable, on the anticipated timelines or at all; even if the acquisition is consummated, the businesses of Alkermes
and Avadel may not be effectively integrated and the expected benefits and value of the acquisition may not be achieved; there may be
significant changes in transaction costs and/or unknown or inestimable liabilities and potential litigation associated with the planned
acquisition; whether any general economic, political, market and business conditions, or future exchange and interest rates, changes
in tax laws, regulations, rates and policies, may have a negative impact on Alkermes, Avadel or the combined organization following consummation
of the planned acquisition; the announcement or pendency of the planned acquisition, including the Increased Offer, could result in disruption
to the business and make it more difficult to maintain business and operational relationships of Alkermes and Avadel, including the ability
of each of Alkermes and Avadel to attract and retain highly qualified management and other clinical and scientific personnel; the possibility
that competing offers may be made for Avadel; clinical development activities may not be initiated or completed on expected timelines
or at all; the results of development activities may not be positive, or predictive of future results from such activities, results of
future development activities or real-world results; Alkermes&rsquo; or Avadel&rsquo;s products or product candidates could be shown
to be ineffective or unsafe; the FDA or regulatory authorities outside the U.S. may not agree with Alkermes&rsquo; or Avadel&rsquo;s
regulatory approval strategies or may make adverse decisions regarding its products; Alkermes or Avadel may not be able to continue to
successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement
for the Alkermes&rsquo; or Avadel&rsquo;s products or an increase in related financial obligations to government payers; Alkermes and
Avadel&rsquo;s products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties,
or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading
 &ldquo;Risk Factors&rdquo; in Alkermes&rsquo; Annual Report on Form&nbsp;10-K for the year ended Dec.&nbsp;31, 2024 and in subsequent
filings made by Alkermes with the SEC, which are available on the SEC&rsquo;s website at </FONT><U>www.sec.gov</U>. Additional information
about economic, competitive, governmental, technological and other factors that may affect Avadel is set forth under the heading &ldquo;Risk
Factors&rdquo; in Avadel&rsquo;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2024 and in subsequent filings
made by Avadel with the SEC, which are available on the SEC&rsquo;s website at <U>www.sec.gov</U>. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required
by law, Alkermes disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this
revised offer announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.5</B></FONT></TD><TD><B>RESPONSIBILITY STATEMENT REQUIRED BY THE TAKEOVER RULES</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Alkermes Directors accept
responsibility for the information contained in this revised offer announcement other than that relating to the Company, the Company Group
and the Company Directors and members of their immediate families, related trusts and persons connected with them but including the Parent
Company Statements (for which the Alkermes Board accepts responsibility), and other than the statements made by the Company in respect
of Alkermes. To the best of the knowledge and belief of the members of the Alkermes Board (who has taken all reasonable care to ensure
that such is the case), the information contained in this revised offer announcement for which they accept responsibility is in accordance
with the facts and does not omit anything likely to affect the import of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Directors accept
responsibility for the information contained in this revised offer announcement relating to the Company and the Company Directors and
members of their immediate families, related trusts and persons connected with them, except for the statements made by Alkermes in respect
of the Company or the Company Group (the &ldquo;<U>Parent Company Statements</U>&rdquo;). To the best of the knowledge and belief of the
Company Directors (who have taken all reasonable care to ensure such is the case), the information contained in this revised offer announcement
for which they respectively accept responsibility is in accordance with the facts and does not omit anything likely to affect the import
of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.6</B></FONT></TD><TD><B>IMPORTANT NOTICES RELATING TO FINANCIAL ADVISORS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Goldman Sachs&nbsp;&amp; Co.
LLC, which is authorized and regulated by the Financial Industry Regulatory Authority, is acting exclusively as financial advisor for
the Company and for no one else in connection with the matters set out in this revised offer announcement and will not regard any other
person as its client in relation to the matters set out in this revised offer announcement and will not be responsible to anyone other
than the Company for providing the protections afforded to clients of Goldman Sachs&nbsp;&amp; Co. LLC nor for providing advice in relation
to the Acquisition or any other matter referred to in this revised offer announcement. Neither Goldman Sachs&nbsp;&amp; Co. LLC nor any
of its affiliates (nor their respective directors, officers, employees or agents) owes or accepts any duty, liability or responsibility
whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of
Goldman Sachs&nbsp;&amp; Co. LLC in connection with this revised offer announcement, any statement contained herein or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Morgan Stanley&nbsp;&amp;
Co. LLC, acting through its affiliate Morgan Stanley&nbsp;&amp; Co. International plc (together, &ldquo;Morgan Stanley&rdquo;), which
is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority in the United Kingdom, is acting
exclusively for the Company as financial advisor and for no one else in relation to the matters referred to in this revised offer announcement.
In connection with such matters, Morgan Stanley and its directors, officers, employees and agents will not regard any other person as
its client, nor will it be responsible to anyone other than the Company for providing the protections afforded to their clients or for
providing advice in connection with the matters described in this revised offer announcement or any matter referred to herein. Neither
Morgan Stanley&nbsp;&amp; Co. LLC nor Morgan Stanley&nbsp;&amp; Co. International plc nor any of their respective affiliates (nor their
respective directors, officers, employees or agents) owes or accepts any duty, liability or responsibility whatsoever (whether direct
or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Morgan Stanley&nbsp;&amp;
Co. LLC in connection with this revised offer announcement, any statement contained herein or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">J.P. Morgan Securities LLC,
together with its affiliate J.P. Morgan Securities plc (which is authorized in the United Kingdom by the Prudential Regulation Authority
and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (together, &ldquo;J.P.
Morgan&rdquo;) are acting as financial advisor exclusively for Alkermes and no one else in connection with the Acquisition and will not
regard any other person as its client in relation to the Acquisition and will not be responsible to anyone other than Alkermes for providing
the protections afforded to clients of J.P. Morgan or its affiliates, nor for providing advice in relation to the Acquisition or any other
matter or arrangement referred to herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.7</B></FONT></TD><TD><B>DISCLOSURE REQUIREMENTS OF THE TAKEOVER RULES</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the provisions of Rule&nbsp;8.3(a)&nbsp;of
the Takeover Rules, any person who is &lsquo;interested&rsquo; (directly or indirectly) in 1% or more of any class of &lsquo;relevant
securities&rsquo; of the Company must make an &lsquo;opening position disclosure&rsquo; following the commencement of the &lsquo;offer
period&rsquo;. An &lsquo;opening position disclosure&rsquo; must contain the details contained in Rule&nbsp;8.6(a)&nbsp;of the Takeover
Rules, including, among other things, details of the person&rsquo;s &lsquo;interests&rsquo; and &lsquo;short positions&rsquo; in any &lsquo;relevant
securities&rsquo; of the Company. An &lsquo;opening position disclosure&rsquo; by a person to whom Rule&nbsp;8.3(a)&nbsp;applies must
be made by no later than 3:30 p.m.&nbsp;(U.S. Eastern Time) on the day falling ten &lsquo;business days&rsquo; following the commencement
of the &lsquo;offer period&rsquo;. Relevant persons who deal in any &lsquo;relevant securities&rsquo; prior to the deadline for making
an &lsquo;opening position disclosure&rsquo; must instead make a &lsquo;dealing&rsquo; disclosure as described below. The offer period
in respect of Avadel in relation to the Acquisition commenced on October&nbsp;22, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the provisions of Rule&nbsp;8.3(b)&nbsp;of
the Takeover Rules, if any person is, or becomes, &lsquo;interested&rsquo; in (directly or indirectly) 1% or more of any class of &lsquo;relevant
securities&rsquo; of the Company, that person must publicly disclose all &lsquo;dealings&rsquo; in any &lsquo;relevant securities&rsquo;
of the Company during the &lsquo;offer period&rsquo;, by no later than 3:30 p.m.&nbsp;(U.S. Eastern Time) on the &lsquo;business day&rsquo;
following the date of the relevant transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If two or more persons cooperate
on the basis of any agreement either express or tacit, either oral or written, to acquire an &lsquo;interest&rsquo; in &lsquo;relevant
securities&rsquo; of the Company or any securities exchange offeror, they will be deemed to be a single person for the purpose of Rule&nbsp;8.3
of the Takeover Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, each of the Company
and any offeror must make an &lsquo;opening position disclosure&rsquo; by no later than 12:00 noon (U.S. Eastern Time) on the date falling
ten &lsquo;business days&rsquo; following the commencement of the &lsquo;offer period&rsquo; or the announcement that first identifies
a securities exchange offeror, as applicable, and disclose details of any &lsquo;dealings&rsquo; by it or any person &lsquo;acting in
concert&rsquo; with it in &lsquo;relevant securities&rsquo; during the &lsquo;offer period&rsquo;, by no later than 12:00 noon (U.S. Eastern
Time) on the business day following the date of the transaction (see Rules&nbsp;8.1, 8.2 and 8.4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A disclosure table, giving
details of the companies in whose &lsquo;relevant securities&rsquo; &lsquo;opening position&rsquo; and &lsquo;dealings&rsquo; should be
disclosed can be found on the Irish Takeover Panel&rsquo;s website at www.irishtakeoverpanel.ie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Interests&rdquo; in
securities arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities.
In particular, a person will be treated as having an &lsquo;interest&rsquo; by virtue of the ownership or control of securities, or by
virtue of any option in respect of, or derivative referenced to, securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Terms in quotation marks in
this section are defined in the Takeover Rules, which can be found on the Irish Takeover Panel&rsquo;s website. If you are in any doubt
as to whether or not you are required to disclose an &lsquo;opening position&rsquo; or &lsquo;dealing&rsquo; under Rule&nbsp;8, please
consult the Irish Takeover Panel&rsquo;s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number
+353 1 678 9020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.8</B></FONT></TD><TD><B>NO PROFIT FORECAST / PROFIT ESTIMATE / QUANTIFIED FINANCIAL BENEFIT STATEMENT / ASSET VALUATIONS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No statement in this revised
offer announcement is intended to constitute a profit forecast, profit estimate or quantified financial benefit statement for any period,
nor should any statements be interpreted to mean that earnings or earnings per share will, for the current or future financial years or
other periods, necessarily be greater or lesser than those for the relevant preceding financial periods for Alkermes or the Company. No
statement in this revised offer announcement constitutes an asset valuation within the meaning of the Takeover Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.9</B></FONT></TD><TD><B>PUBLICATION ON WEBSITE</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Rule&nbsp;26.1
of the Takeover Rules, a copy of this revised offer announcement will be available on the Company&rsquo;s website at www.avadel.com and
on Alkermes&rsquo; website at www.alkermes.com by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication
of this revised offer announcement. Neither the content of any such websites referred to in this revised offer announcement nor the content
of any other websites accessible from hyperlinks on such website is incorporated into, or forms part of, this revised offer announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.10</B></FONT></TD><TD><B>REQUESTING HARD COPY INFORMATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Company Shareholder may
request a copy of this revised offer announcement and / or any information incorporated by reference into this revised offer announcement
in hard copy form by writing to the Company, Attn: Investor Relations, 16640 Chesterfield Grove Road #200, Chesterfield, MO 63005, United
States or by contacting Investor Relations, via email at&nbsp;investors@avadel.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any written requests must
include the identity of the Company Shareholder and any hard copy documents will be posted to the address of the Company Shareholder provided
in the written request. If you have received this revised offer announcement in electronic form, a hard copy of this revised offer announcement
and / or any document or information incorporated by reference into this revised offer announcement will not be provided unless such a
request is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.11</B></FONT></TD><TD><B>RIGHT TO SWITCH TO A TAKEOVER OFFER</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alkermes reserves the right
to elect to implement the Acquisition by way of a Takeover Offer for the entire issued and to be issued ordinary share capital of the
Company as an alternative to the Scheme, subject to the provisions of the Takeover Rules&nbsp;and the Transaction Agreement (as amended
by Amendment No.&nbsp;1 to the Transaction Agreement) and with the Irish Takeover Panel&rsquo;s consent, whether or not the Scheme Document
has been posted. In such event, the Acquisition would be implemented on the same terms (subject to appropriate amendments, including without
limitation an acceptance condition set at 80% of the shares to which such offer relates, or such lesser percentage being more than 50%,
as Alkermes may, with the consent of the Company and the Panel (if required) decide) so far as are applicable, as those which would apply
to the Scheme and subject to the amendments referred to in Appendix III (<I>Conditions of the Acquisition and the Scheme</I>) to the October&nbsp;2.7
Announcement and in the Transaction Agreement (as amended by Amendment No.&nbsp;1 to the Transaction Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Alkermes exercises its
right to implement the Acquisition by way of a Takeover Offer as an alternative to the Scheme, subject to the provisions of the Takeover
Rules&nbsp;and the Transaction Agreement (as amended by Amendment No.&nbsp;1 to the Transaction Agreement) and with the Irish Takeover
Panel&rsquo;s consent, such offer would be made in compliance with applicable U.S. Laws and regulations, including the registration requirements
of the Securities Act and the tender offer rules&nbsp;under the Exchange Act and any applicable exemptions provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.12</B></FONT></TD><TD><B>ROUNDING</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain figures included in
this revised offer announcement have been subjected to rounding adjustments. Accordingly, any figures shown for the same category presented
in different tables may vary slightly and figures shown as totals in certain tables may not be an arithmetic aggregation of the figures
that precede them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.13</B></FONT></TD><TD><B>OVERSEAS JURISDICTIONS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The release, publication or
distribution of this revised offer announcement in or into jurisdictions other than Ireland and the United States may be restricted by
Law and therefore any persons who are subject to the Law of any jurisdiction other than Ireland and the United States should inform themselves
about, and observe, any applicable legal or regulatory requirements. In particular the ability of persons who are not resident in Ireland
or the United States, to vote their Company Shares with respect to the Scheme at the Scheme Meeting, or to appoint another person as proxy
to vote at the Scheme Meeting on their behalf, may be affected by the Laws of the relevant jurisdictions in which they are located. Any
failure to comply with the applicable legal or regulatory requirements may constitute a violation of the Laws of any such jurisdiction.
To the fullest extent permitted by applicable Law, the Company, Alkermes and persons involved in the Acquisition disclaim any responsibility
or liability for the violation of such restrictions by any person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This revised offer announcement
has been prepared for the purpose of complying with the Laws of Ireland and the Takeover Rules&nbsp;and the information disclosed may
not be the same as that which would have been disclosed if this revised offer announcement had been prepared in accordance with the Laws
of jurisdictions outside of Ireland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise determined
by Alkermes or required by the Takeover Rules, and permitted by applicable Law and regulation, the Acquisition will not be made available
directly or indirectly, in, into or from any Restricted Jurisdiction and no person may vote in favor of the Acquisition by any use, means,
instrumentality or facilities from within a Restricted Jurisdiction or any other jurisdiction if to do so would constitute a violation
of the Laws of that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The release, publication or
distribution of this revised offer announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions.
Accordingly, copies of this revised offer announcement and any formal documentation relating to the Acquisition will not be and must not
be, directly or indirectly, published, mailed or otherwise forwarded, distributed or sent in, into or from any Restricted Jurisdiction
or any jurisdiction where to do so would violate the Laws of that jurisdiction and persons receiving such documents (including, without
restriction, custodians, nominees and trustees) must not mail or otherwise forward, distribute or send them in or into or from any Restricted
Jurisdiction. Doing so may render invalid any related purported vote in respect of the Acquisition. If the Acquisition is implemented
by way of a Takeover Offer (unless otherwise permitted by applicable Law or regulation), the Takeover Offer may not be made, directly
or indirectly, in or into or by use of the mails or any other means, instrumentality or facilities (including, without limitation, facsimile,
email or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or any facility of a national, state
or other securities exchange of any Restricted Jurisdiction and the Takeover Offer will not be capable of acceptance by any such use,
means, instrumentality or facilities from within any Restricted Jurisdiction or any other jurisdiction if to do so would constitute a
violation of the Laws of that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further details in relation
to overseas shareholders will be contained in the definitive Proxy Statement (which will include the Scheme Document).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SOURCES AND BASES OF INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">In this revised offer announcement, unless otherwise stated or the context otherwise requires, the following
sources and bases of information have been used:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The historical share prices for Avadel are sourced from Nasdaq;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The value of the whole of the existing issued share capital of the Company is based upon the entire issued
ordinary share capital excluding treasury shares at November&nbsp;17, 2025, namely 97,991,088 Company Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The entire issued and to be issued ordinary share capital (fully diluted share capital) of the Company
is calculated on the basis of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the number of issued Company Shares, as set out in paragraph (b)&nbsp;above; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">218,675 issued Company RSU Awards;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">11,641,986 Company Options; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">466,000 Company Performance Options;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Save where otherwise stated, financial and other information concerning Alkermes and the Company has been
extracted from published sources or from audited financial results of Alkermes and the Company; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">References to the arrangements in place between Alkermes and the Company regarding a transaction agreement
are sourced from the Transaction Agreement (as amended by Amendment No.&nbsp;1 to the Transaction Agreement).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>avdl-20251118.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaaA2bOdzZR+iYkxtmBwbcn6nyohj9nTvyWMfe5m0bgL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:avdl="http://avadel.com/20251118" elementFormDefault="qualified" targetNamespace="http://avadel.com/20251118">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://avadel.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="avdl-20251118_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avdl-20251118_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>avdl-20251118_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>avdl-20251118_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="avdl-20251118.xsd#Cover" roleURI="http://avadel.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://avadel.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 18,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AVADEL PHARMACEUTICALS PLC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001012477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1341933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10
        Earlsfort Terrace<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D02
T380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1 901 5201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary
Shares, nominal value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVDL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2529228d13_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://avadel.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avdl-20251118.xsd</File>
    <File>avdl-20251118_lab.xml</File>
    <File>avdl-20251118_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2529228d13_8k.htm">tm2529228d13_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2529228d13_8k.htm": {
   "nsprefix": "avdl",
   "nsuri": "http://avadel.com/20251118",
   "dts": {
    "schema": {
     "local": [
      "avdl-20251118.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "avdl-20251118_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avdl-20251118_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2529228d13_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://avadel.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2529228d13_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-11-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2529228d13_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://avadel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-25-113886-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-113886-xbrl.zip
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M:="M'!>HDKGEZ!16OQU_D4,B<U 2:^T,E'"-A!%];U<\W<3=Z?R)F3S+HX;
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M-2=9<I85]JY9A/.BUWMW@T"%_-]8R\9RT_AX.CXY/MIE\4@?_.((<I:2>_*
MBF:>Y?MG05*62!!&Y;9'3A[L9E+.)S)^0LD:YR26.SJ5.SK^7N[HK^7F:[PB
MZ0A)I> #;-=IHZXR:.+:[!WA"8LOZ?M<F]&>[(OO#L__AP;4XYTW8<ERG+[+
M?#W2N>T;\KXC?HAS?Z3%,$_>=Z1KD?\7VWG;\IL/K_VXIG+CM?C4L$AVN9C
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MPN5[!TNRRS^+'3UUG&$,B'5]]C:X.>;)7&]@$!"^U2UTJI>A>@5H)9\1*ZM
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MO!O6XXXW8[:(&^.2L(.M]VQ@@TYXQ>P A%G(78M;&!</[-'$"4V7>Y/ F;,
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M&R1IKMD"B>UTMF>61YH*K"9F4$N>)!<-#\6"("\$D]XW7)70R]&S[Q. GLA
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M<]GJ/,WB/ /^2J@AU$)((,#V$9N,Q]SOFVB"BYVW/L(M">_7JT0IH:RNYS0
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MQ)" M7J355O-9JV*^GSTRJA4/US"I+LT[1A0!"GN'9ZWVA>M=@5ONG[[.P
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MBX^U*A*U5.Q^@"4A50Y1RH @&S KE(]) 3:V504SQM@R;S\'7Z R:76+!U-
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M#V_>"(QL]SQKCO\.PY%S_/]02P,$%     @ ]#)S6TQ,[K^)%0  W78  !8
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MAE<IAE'$#9]!B/A^DB6^%R@[$/VLM%$_FJS=$XC5B3$7C@%^0I;DP-4=%Q5
M8IT!IU-::D_+"/1^3^@Q.U((?P!(R:P* ZKY*R3I1ZE!3,K46W<P0+$#('9
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M259AD(?;K;)I?QT!>8N]7$&94;XRIHG9N;GO 4UG$>8Y+.%CL-FV5))S%7B
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M: H+D!1>4-E)OABG@B3R&)9@D2 FAW0T8@;);6.D]$ZS+,N;8B,KT3N?CJ/
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M)-!MI2B(RZNT7&?IN!69R%+*1>6WUXFU6<3WQ4/$=Z.([XN'B.^/(%'/'45
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M+8WG54NC-C?,8";=4[-CN(J%HA,(.+A;1WIC_*@6V<R35=DLJ)?,T@FW*:9
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MFOIOC_7N,V.P^J>Z54KTI[0<@FJ89QA4$AR4(.9H-&791+"B*TX<KS!7]7"
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M++*4&.EH-SX6(VKY.WD$8V=+OZ\9&L-!O@G"QW8+L>9#-U=8899L#EIT0*X
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M=]X.Q94JP X)WUVG:$N[;&*AO-+1; 0ZAJ0$Z6C"S7:>6G0QWS(Q6$P$,F9
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MU@7S?+S\'JJM&A'Y<YSK<C',F0XG.M=KBV5RO'1]"S%P.3A7N_^DG$9,"!9
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MA,3P7=B0IM9@O/J%M'[ ;><7&*=)%IAHWFS\SY-G3]2N>O[B)?:4W'F(<_S
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MT!Y1<14Y#TR4C&K^P2)_N?-/O1VTW1+%("!#VZF!D6$X1D4_BR,/S%54D%"
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MGMM@G,ZID=QF23<"ES?#[H,2\-!>/1^,?M51H7X26!5)J%$C6*55AX56+[_
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M&'X\>OO_ U!+ 0(4 Q0    ( /0R<UO39%3=)0,  -P+   1
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M2P$"% ,4    " #T,G-;3$SNOXD5  #==@  %@              @ $81
M=&TR-3(Y,C(X9#$S7V5X,BTR+FAT;5!+ 0(4 Q0    ( /0R<UMP2UPKD6L
M %5& @ 7              "  =59  !T;3(U,CDR,CAD,3-?97@Y.2TQ+FAT
7;5!+!08     !@ & (\!  ";Q0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tm2529228d13_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="avdl-20251118.xsd" xlink:type="simple"/>
    <context id="AsOf2025-11-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <startDate>2025-11-18</startDate>
            <endDate>2025-11-18</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-11-18" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-11-18" id="Fact000004">0001012477</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-11-18" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-11-18" id="Fact000011">2025-11-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-11-18" id="Fact000012">AVADEL PHARMACEUTICALS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-11-18" id="Fact000013">L2</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-11-18" id="Fact000014">001-37977</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-11-18" id="Fact000015">98-1341933</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-11-18" id="Fact000016">10         Earlsfort Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-11-18" id="Fact000017">Dublin 2</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AsOf2025-11-18" id="Fact000018">IE</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-11-18" id="Fact000019">D02 T380</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-11-18" id="Fact000020">353</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-11-18" id="Fact000021">1 901 5201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-11-18" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-11-18" id="Fact000023">true</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-11-18" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-11-18" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-11-18" id="Fact000026">Ordinary Shares, nominal value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-11-18" id="Fact000027">AVDL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-11-18" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-11-18" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
